


CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2017



NATIONAL CANCER CONTROL PROGRAMME
MINISTRY OF HEALTH

National Cancer Incidence and Mortality Data

Sri Lanka

2017



National Cancer Control Programme,
555/5, Public Health Complex,
Elvitigala Mawatha,
Narahenpita, Colombo 5,
Sri Lanka.

19th Publication - National Cancer Incidence and Mortality Data Sri Lanka: 2017

Published in October 2021

ISBN 978-624-5719-15-0

Compiled by

Strategic Information Management (SIM) Unit,
National Cancer Control Programme,
Ministry of Health

Published by



National Cancer Control Programme,
Ministry of Health,
555/5, Public Health Complex,
Elvitigala Mawatha,
Narahenpita, Colombo 05,
Sri Lanka.

Contact No +94 112368627, Fax +94 112368627

Email - nccpsl@yahoo.com

Web - www.nccp.health.gov.lk



National Cancer Control Programme, Sri Lanka.

Printed by: P & G Printers (Pvt) Ltd,
Colombo 10, Sri Lanka.
Tel - 011 2447722
www.pandgprinters.com

Table of Contents

	Page No.
Table of Contents	iii
List of Tables	iv
List of Figures	v
Message from the Director General of Health Services	vii
Message from Deputy Director General (Non-Communicable Diseases)	ix
Foreword	xi
Contributors	xiii
Acknowledgements	xiv
Executive Summary	1
Cancer Incidence & Mortality Data Sri Lanka - 2017	5
1. Introduction	5
2. Methodology	5
Cancer Incidence Data of Sri Lanka – 2017	12
Cancer Mortality Data of Sri Lanka	110
Annex	112
List of References	114

List of Tables

Table No.	Description	Page No.
Table 1:	Cancer Incidence by sex in Sri Lanka, 2005- 2017	13
Table 2:	Cancer Incidence by 5-year age groups and sex in Sri Lanka 2017	15
Table 3:	Leading cancer site by sex in Sri Lanka – 2017	16
Table 4:	Number of cancers by five – year age groups and ICD 10 site, among males in Sri Lanka in 2017	24
Table 5:	Number of cancers by five – year age groups and ICD 10 site, among females in Sri Lanka in 2017	29
Table 6:	Number of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka 2017	33
Table 7:	Number of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka 2017	34
Table 8:	Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka, 2017	35
Table 9:	Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka, 2017	36
Table 10:	Lip, Tongue and Mouth cancer incidence data in Sri Lanka, 2017	37
Table 11:	Pharyngeal cancer incidence data in Sri Lanka, 2017	40
Table 12:	Oesophageal cancer incidence data in Sri Lanka, 2017	42
Table 13:	Stomach cancer incidence data in Sri Lanka, 2017	44
Table 14:	Colon and rectal cancer incidence data in Sri Lanka, 2017	46
Table 15:	Laryngeal cancer incidence data in Sri Lanka, 2017	48
Table 16:	Trachea, Bronchus and Lung cancer incidence data in Sri Lanka, 2017	50
Table 17:	Skin cancer incidence data in Sri Lanka, 2017	53
Table 18:	Breast cancer incidence data in Sri Lanka, 2017	56
Table 19:	Cervix uteri cancer incidence data in Sri Lanka, 2017	59
Table 20:	Uterine cancer incidence data in Sri Lanka, 2017	61
Table 21:	Ovarian cancer incidence data in Sri Lanka, 2017	63
Table 22:	Prostate cancer incidence data in Sri Lanka, 2017	66
Table 23:	Urinary Bladder cancer incidence data in Sri Lanka, 2017	68
Table 24:	Thyroid gland cancer incidence data in Sri Lanka, 2017	70
Table 25:	Lymphoma incidence data in Sri Lanka, 2017	72
Table 26:	Leukaemia incidence data in Sri Lanka, 2017	75
Table 27:	Basis of diagnosis of cancer patients in Sri Lanka, 2017	79
Table 28:	Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2017 according to International Classification of Childhood Cancer third edition (ICCC-3) by sex	81
Table 29:	Overall cancer incidence by province and district in Sri Lanka, 2017	89
Table 30:	Leading cancer incidence data by district in Sri Lanka, 2017	90
Table 31:	Deaths due to cancers among males & females in hospitals in Sri Lanka, 2012-2017	110
Table 32:	Deaths due to cancers in hospitals, crude hospital annual death rates due to cancers and proportionate mortality ratio for cancers out of all hospital deaths in Sri Lanka, 2005-2017	110
Table 33:	Hospitalizations, hospital deaths and case fatality rate due to cancers in year 2017 by RDHS divisions in Sri Lanka	111

List of Figures

Figure No.	Description	Page No.
Figure 1:	Population pyramid of Sri Lanka in 2017 by 5-year age groups	12
Figure 2:	Crude Cancer Incidence Rates of Sri Lanka, 2005-2017	14
Figure 3:	Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2017	14
Figure 4:	Cancer Incidence Rates of Sri Lanka in 2017	15
Figure 5:	Age Specific Cancer Incidence Rates in Sri Lanka 2017	16
Figure 6:	Proportion of leading cancers in males in Sri Lanka - 2017	17
Figure 7:	Proportion of leading cancers in females in Sri Lanka - 2017	17
Figure 8:	Crude incidence rates of leading cancers in males in Sri Lanka - 2017	18
Figure 9:	Crude incidence rates of leading cancers in females in Sri Lanka - 2017	18
Figure 10:	Leading cancers by 0-14 year age group among males in Sri Lanka in 2017	19
Figure 11:	Leading cancers by 0-14 year age group among females in Sri Lanka in 2017	19
Figure 12:	Leading cancers by 15 -34 year age group among males in Sri Lanka in 2017	20
Figure 13:	Leading cancers by 15 -34 year age group among females in Sri Lanka in 2017	20
Figure 14:	Leading cancers by 35 - 49 year age group among males in Sri Lanka in 2017	21
Figure 15:	Leading cancers by 35 - 49 year age group among females in Sri Lanka in 2017	21
Figure 16:	Leading cancers by 50 - 64 year age group among males in Sri Lanka in 2017	22
Figure 17:	Leading cancers by 50 - 64 year age group among females in Sri Lanka in 2017	22
Figure 18:	Leading cancers by 65 years & above age group among males in Sri Lanka in 2017	23
Figure 19:	Leading cancers by 65 years & above age group among females in Sri Lanka in 2017	23
Figure 20:	Age specific rates of Lip, Tongue & Mouth cancer in Sri Lanka in 2017	39
Figure 21:	Age standardized incidence rates of Lip, Tongue & Mouth cancer in Sri Lanka, 2005 - 2017	39
Figure 22:	Age specific rates of Pharyngeal cancer in Sri Lanka in 2017	41
Figure 23:	Age standardized incidence rates of Pharyngeal cancer in Sri Lanka, 2012 - 2017	41
Figure 24:	Age specific incidence rates of Oesophageal cancer in Sri Lanka in 2017	43
Figure 25:	Age standardized incidence rates of Oesophageal cancer in Sri Lanka, 2005 - 2017	43
Figure 26:	Age specific incidence rates of Stomach cancer in Sri Lanka in 2017	45
Figure 27:	Age standardized incidence rates of Stomach cancer in Sri Lanka, 2005 - 2017	45
Figure 28:	Age specific incidence rates of Colon and Rectal cancer in Sri Lanka in 2017	47
Figure 29:	Age standardized incidence rates of Colon and Rectal cancer in Sri Lanka, 2005 – 2017	47
Figure 30:	Age specific incidence rates of Laryngeal cancer in Sri Lanka in 2017	49
Figure 31:	Age standardized incidence rates of Laryngeal cancer in Sri Lanka, 2005 - 2017	49
Figure 32:	Age specific incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka in 2017	52
Figure 33:	Age standardized incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka, 2005–2017	52
Figure 34:	Age specific incidence rates of Skin cancer in Sri Lanka in 2017	55
Figure 35:	Age standardized incidence rates of Skin cancer in Sri Lanka, 2005 - 2017	55
Figure 36:	Age specific incidence rates of Breast cancer in Sri Lanka in 2017	58
Figure 37:	Age standardized incidence rates of Breast cancer in Sri Lanka, 2005 - 2017	58
Figure 38:	Age specific incidence rates of Cervical cancer in Sri Lanka in 2017	60
Figure 39:	Age standardized incidence rates of Cervical cancer in Sri Lanka, 2005 - 2017	60
Figure 40:	Age specific incidence rates of Uterine cancer in Sri Lanka in 2017	62
Figure 41:	Age standardized incidence rates of Uterine cancer in Sri Lanka, 2005 - 2017	62
Figure 42:	Age specific incidence rates of Ovarian cancer in Sri Lanka in 2017	65
Figure 43:	Age standardized incidence rates of Ovarian cancer in Sri Lanka, 2005 - 2017	65
Figure 44:	Age specific incidence rates of Prostate cancer in Sri Lanka in 2017	67
Figure 45:	Age standardized incidence rates of Prostate cancer in Sri Lanka, 2005 - 2017	67

Figure No.	Description	Page No.
Figure 46:	Age specific incidence rates of Urinary Bladder cancer in Sri Lanka in 2017	69
Figure 47:	Age standardized incidence rates of Urinary Bladder cancer in Sri Lanka, 2005 - 2017	69
Figure 48:	Age specific incidence rates of Thyroid gland cancer in Sri Lanka in 2017	71
Figure 49:	Age standardized incidence rates of Thyroid gland cancer in Sri Lanka, 2005 - 2017	71
Figure 50:	Age specific incidence rates of Lymphoma in Sri Lanka in 2017	74
Figure 51:	Age standardized incidence rates of Lymphoma in Sri Lanka, 2011 - 2017	74
Figure 52:	Age specific incidence rates of Leukaemia in Sri Lanka in 2017	77
Figure 53:	Age standardized incidence rates of Leukaemia in Sri Lanka, 2011 - 2017	77
Figure 54:	Clinical stage at diagnosis of Breast cancers in Sri Lanka, 2017	78
Figure 55:	Clinical stage at diagnosis of Cervical cancers in Sri Lanka, 2017	78
Figure 56:	Clinical stage at diagnosis of Lip, Tongue and Mouth cancers in Sri Lanka, 2017	78
Figure 57:	Basis of diagnosis of cancers in Sri Lanka, 2017	79
Figure 58:	Percentage of newly detected cancer patients who received different types of treatment in Sri Lanka, 2017	80
Figure 59:	Cancer incidence by districts among males in Sri Lanka, 2017	100
Figure 60:	Cancer incidence by districts among females in Sri Lanka, 2017	105

Message from the Director General of Health Services



It is with great pleasure that I send this message to the publication of the '**National Cancer Incidence and Mortality Data, Sri Lanka – 2017**', a product of the National Cancer Control Programme (NCCP) of Ministry of Health, which was generated to carry noteworthy information on the cancer burden of the whole country.

The information in this document would support and enhance the process of planning, implementing, monitoring and evaluation of cancer prevention and control of Sri Lanka.

I would like to express my sincere appreciation to the World Health Organization for their partnership offered to clear the backlog of cancer incidence data, enabling the due publication of the cancer registry data.

Finally, I would like to acknowledge the hard work of the National Cancer Control Programme and the contributions of other stakeholders including hospital administrators, Oncology units, Oro-maxillo facial units and the Pathology laboratories (histopathology, haematology, oral pathology) to make this publication a success.

Dr. Asela Gunawardena,
Director General of Health Services.

Message from the Deputy Director General (Non -Communicable Diseases)



I am pleased to announce this occasion of the release of 19th edition of the **Cancer Incidence & Mortality Data, Sri Lanka – 2017**, published by the National Cancer Control Programme (NCCP).

Strengthening of cancer surveillance system in the country is essential to provide accurate and timely data to assess the cancer burden, thereby combat Non-Communicable Disease burden of the country. The information generated from this cancer registry publication is essential for planning, implementation, monitoring and evaluation of the cancer control programme of the country.

The valuable partnership of the World Health Organization in clearing the backlog of cancer incidence data, facilitated the release of this publication.

I would like to congratulate the Director and the whole staff of the National Cancer Control Programme for their untiring efforts in make this publication a reality.

Dr. Champika Wickramasingha,
MBBS, MSc, MD (Community Medicine)
Deputy Director General (Non-Communicable Diseases)

Foreword



National Cancer Control Programme (NCCP) of Ministry of Health would like to release 19th edition of 'Cancer Incidence & Mortality Data, Sri Lanka - 2017'. The contributions received from the stakeholders from the points of diagnosis (histopathology, haematology, oral pathology laboratories) points of treatment (specialized cancer treatment units, other units treating cancer patients) and points of death (divisional death registrar officers). In addition, cancer related mortality data published by the Registrar General Department and Department of Census & Statistics are incorporated for the publication to generate a comprehensive picture of cancer mortality data.

World Health Organization (WHO) country office, Colombo has provided technical support for cancer surveillance throughout the period. Especially WHO country office for providing partnership to clear the backlog is highly appreciated. Partnership given by Dr. Nalika Gunawardana, National Professional Officer (NPO), WHO country office is highly appreciated.

The National Cancer Control Programme would like to express special thank for all government cancer treatment centers, all government pathology laboratories, all government Oral and Maxillo- Facial surgery units and private sector hospitals for providing necessary data.

I acknowledge the contribution given by the Multi Tech Solution (Pvt) Ltd to complete this endeavor. In addition to that contribution from Cancer Care Association is appreciated.

I would like to thank the untiring effort of National Cancer Control Programme team for generating this publication and mitigating measures to clear the backlog of publishing cancer incidence data of subsequent years.

Dr. Janaki Vidanapathirana
MBBS, MSc, MD (Community Medicine)
Director, National Cancer Control Programme

Contributors

Data coding

Dr. K. G. Nirmala Jayanthi	Dr. Dulanjali Laxamana	Ms. Sachini Sashikala
Dr. Pushpika Samarakoon	Dr. Thanuja Wickramatunga	Mrs. Pubudika Amarasingha
Dr. Ruvanmalie Liyanagama	Dr. Imalka Suriyapperuma	Ms. Chammi Balasooriya
Dr. Tevini Vitharana	Mrs. Chamila Peiris	
Dr. Chathurika Jayamani	Mrs. Sunethra Kasthuri	

Data entry & duplicate checking at the centre

Mrs. Nimesha Prasadi	Mrs. Nayomi Weerasingha
----------------------	-------------------------

Duplicate checking & data verification

Dr. Suraj Perera	Dr. Chathurika Jayamani	Dr. K.G. Nirmala Jayanthi
Dr. Nirma Alapitiarachchi	Dr. Thanuja Wickramatunga	Mrs. Chamila Peiris
Dr. Tevini Vitharana	Dr. Chulaka Jayaweera	Ms. Sachini Sashikala

Statistical analysis and report writing

Dr. Thanuja Wickramatunga	Dr. K.G. Nirmala Jayanthi	Dr. Suraj Perera
---------------------------	---------------------------	------------------

Infographics

Dr. Chathurika Jayamani

GIS Maps

Dr. Ruwanika Seneviratne & Dr. D.V.S. Wijekoon of Anti Malaria Campaign

Support staff

Mr. Saman Kumara Mahalekam Mrs. Deepa Pathmanjali
Mrs. Thushari Dammika

Overall Coordination

Dr. Suraj Perera,
Consultant Community Physician,
Strategic Information Management Unit, National Cancer Control Programme

Acknowledgements

National Advisory Committee on Prevention & Control of Cancers

Technical Advisory Committee on Cancer Registration & Research

All the government cancer treatment centers

All pathology laboratories, Oral and Maxillo- Facial surgery unit

Private hospitals

Professional Colleges – College of Oncologists, College of Pathologists, College of Haematologists

Association of Oral Pathology & Oral Medicine

World Health Organization- Country Office, Sri Lanka

Multi Tech Solutions (Pvt) Ltd

Cancer Care Association – Sri Lanka

Executive summary

Cancer Incidence and Mortality Data, Sri Lanka- 2017 is the 19th volume of the series of publication on cancer surveillance data, Sri Lanka. National Cancer Registry Sri Lanka is based on the newly reported cancers in the year 2017. The newly detected cancers through the government cancer treatment centers, pathology laboratories, Oral and Maxillo Facial (OMF) surgery units in the country were considered for this publication. All the data were entered in to the 'Can Reg 5'data base. Quality checks were conducted and duplicate entries were eliminated. Analysis was done by Can Reg 5 and SPSS software. For Cancer mortality data, mortality data published at the Annual Health Bulletin – 2017 were analyzed.

In the year 2017, a total number of 32,170 new patients were newly diagnosed with cancer, giving crude incidence rate (CR) of 150 per 100,000 population. Crude incidence rate of males was 148.9/100,000 and Crude incidence rate of females was 151.1/100,000 population. The highest 5- year age specific incidence rates were reported among males and females of 70- 74-year age group (Males 1071.0/100 000 and females 697.4 /100 000). When age standardized rates (ASR) were considered, the overall ASR was 132.7/100 000 and the ASR for males and females were 140.2/100 000 and 128.8/100 000.

Lip, tongue and mouth cancers (n=2249, CR= 21.7/100 000), Trachea, bronchus and lung cancers (n=1338, CR= 12.9/100 000), Colon and rectal cancers (n= 1289, CR= 12.4/100 000) and oesophageal cancers (n=1167, CR = 11.2/100 000) were the highest incident cancers among males. Except Pharyngeal cancers crude rates of all other leading male cancers there were slight reduction of crude incidence rate in comparison to the similar figure in year 2016. Even though ASR of lip, tongue and mouth cancer among males has reduced from 22.9/100,000 to 20.0/100,000 in 2017 in comparison to 2016, still out of all male cancers, 14.5% were lip, tongue and mouth cancers.

Breast (n= 4193, CR= 37.9/100 000), Thyroid (n=2014, CR= 18.2/100 000), Colon and Rectum cancers (n= 1333, CR= 12.1/100 000) and cervix uteri cancers (n=1071, CR=9.7/100 000) were the highest incident cancers among females. Except Uterine cancers, crude rates of all other leading female cancers there were slight reduction of crude incidence rate in comparison to the similar figure in year 2016. Increased trend of breast cancer was observed over the years from 2005 to 2017 (CR=18.4/100 000 to 37.9/100 000).

Cumulative rate of developing cancer between the age group of 0-74 years males is 17.42% and females is 15.03%. It means that among 1 in 5.7 males and 1 in 6.6 females have risk of developing cancer during their life time.


Staging information was available for 13% breast cancers, 30% cervical cancers and 8% lip tongue and mouth cancers. Among those with staging information 39.1% breast cancers, 38.7% cervical cancers and 58.2% lip, tongue and mouth cancers were diagnosed at the advanced stages (Stage III and IV).

Out of all cancers 93.0 % were diagnosed microscopically and histopathology details were available for 87.9% cancers. There were 862 cases of childhood cancers (age between 0-19 Years) and 25.1 % were leukaemias.


Highest number of cancers were reported from Colombo district (n=4639, CR=191.8), Gampaha district (n=1929, CR= 80.7), Kurunegala district (n=1813, CR=107.0), Kandy district (n=1342, CR=92.4) and Kalutara district (n=1182, CR=93.0). A total of 4938 deaths were occurred due to cancers at government hospital settings in year 2017 according to Annual Health Bulletin, 2017.

Cancer Incidence, 2017


New cases **32170**



15458 16712




Crude cancer incidence rates of Sri Lanka
2005 -2017




Number of cases and Crude Incidence Rates of leading cancer sites by sex in Sri Lanka,
2017

(CR per 100 000 population)



ASR of five most common male cancers
from 2005 - 2017



ASR of five most common female cancers
from 2005 - 2017

Childhood cancers


(0-19 years)



862
Cases



Number of Cases of Childhood Cancers
from 2011 to 2017



Percentage Composition of Childhood
Cancers - 2017

Cancer Incidence & Mortality Data Sri Lanka - 2017

1. Introduction


Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates surveillance of cancers in Sri Lanka with the active participation of other stakeholders for cancer surveillance including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) units, professional colleges, WHO country office etc. The process of surveillance of cancers is technically guided by the International Agency for Research on Cancer (IARC) of WHO and WHO IARC Regional Hub for Cancer Registration, Mumbai India. In addition, technical guidance is received from Department of Epidemiology, Bio statistics and Cancer Registry, WIA Cancer Institute, Chennai India.

The information based on surveillance of cancers is published as a publication named 'Cancer Incidence & Mortality Data Sri Lanka'. Up to now 18 volumes have been published (Annex – Table I). This publication is the 19th volume of Cancer Incidence & Mortality Data Sri Lanka.

2. Methodology

The methodology of each step of cancer surveillance is described below.



2.1 Collection of cancer incidence data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) units throughout the country.

2.1.1 Newly registered cancer patients at the cancer treatment centres

In the year 2017, there were 19 government cancer treatment centres involved in data collection (Table i). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form – H 1256'. Data were extracted by the medical officers, nursing officers and development officers attached to the cancer treatment centres, trained pre-intern medical graduates temporarily recruited through WHO Biennium funds and by the cancer registry staff of NCCP.

Table (i) Distribution of government cancer treatment centres in year 2017

Category of hospital	Name of the hospital
National Hospitals	Apeksha Hospital - Maharagama (National Cancer Institute) National Hospital – Kandy
Teaching Hospitals	Karapitiya, Anuradhapura, Batticaloa, Ratnapura
Provincial General Hospitals	Badulla, Kurunegala,
District General Hospital	Gampaha, NuwaraEliya, Hambanthota, Vavuniya, Polonnaruwa, Monaragala, Trincomalee, Ampara, Chilaw, Kegalle
Base Hospital	Tellippalai (Jaffna)

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 52 Histopathology laboratories (18,645 diagnosed patients), eight Haematology laboratories (312 diagnosed patients) and one oral pathology laboratory (316 diagnosed patients) have passively sent relevant data for the year 2017 (Table ii).

Table (ii) Distribution of pathology laboratories which sent details of newly diagnosed cancer patients in year 2017

Category of hospital	Type of Pathology laboratory		
	Histopathology	Haematology	Oral Pathology
National Hospital	National Hospital of Sri Lanka, National Hospital – Kandy, National Eye Hospital, National Hospital for Respiratory Diseases – Welisara		
Teaching Hospitals	De Soysa Hospital for Women, Lady Ridgeway Hospital, Colombo South, Colombo North, Karapitiya, Mahamodara, Anuradhapura, Peradeniya, Sirimavo Bandaranaike Children Hospital, Batticaloa, Jaffna, Ratnapura	Karapitiya, Ratnapura	

Table (ii) continued ...

Category of hospital	Type of Pathology laboratory		
	Histopathology	Haematology	Oral Pathology
Provincial General Hospitals	Kurunegala, Badulla	Kurunegala	
District General Hospitals	Avissawella, Gampaha, Negombo, Kalutara, Matara, Hambanthota Kegalle, Chilaw, Polonnaruwa, Nawalapitiya, Nuwaraeliya, Matale, Trincomalee, Vavuniya	Kalutara, Chilaw, Trincomalee	
Base Hospital	Homagama, Mulleriyawa, Wathupitiwala, Kethumathi, Panadura, Balapitiya, Tangalle, Elpitiya Embilipitiya, Balangoda, Kuliyapitiya, Gampola, Diyathalawa, Karawanella, Puttlam, Thambuttegama	Elpitiya, Kuliyapitiya,	
University Units	Faculty of Medicine – Colombo, Ruhuna, Jayawardeneepura		Faculty of Dental Sciences – Peradeniya
Private sector	Delmons Hospital – Colombo		

2.1.3 Newly diagnosed cancers at the Oral & Maxillo - Facial (OMF) Surgery Units

Data on newly confirmed cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received annually through the Annual Notification Form of Oral Cancer (H -1294). A total of 23 OMF units have sent relevant data for year 2017 (Table iii).

Table (iii) Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2017

Category of hospital	Name of the hospital
National Hospital	Dental Institute – Colombo, National Hospital - Kandy
Teaching Hospitals	Colombo South, Colombo North, Karapitiya, Anuradhapura, Jaffna, Rathnapura
Provincial General Hospitals	Kurunegala
District General Hospitals	Gampaha, Kalutara, Polonnaruwa, Avissawella, Hambanthota, Matale, Negombo, NuwaraEliya, Trincomalee, Vavuniya, Matara, Chilaw
Base Hospital	Kuliyapitiya, Panadura
University Units	-

2.1.4 Population Based Cancer Registry – Colombo district

Two additional data sources were identified for capturing additional cancer incidence data from Colombo district when commencing the Population Based Cancer Registry and those data sources were also incorporated as data generating centres for national cancer registry.

a. Details from Medical Record Departments of Colombo district & adjacent districts

The information on cancer patients treated at the secondary and tertiary care hospitals in the government sector, private sector and armed services in the Colombo district and selected hospitals in the adjacent districts were collected through the 'Cancer Return Form -2' (H-1291). A total of 21 Medical Record Departments have sent the details in year 2017 (Table iv).

Table (iv) Distribution of Medical Record Departments which have sent the details of newly diagnosed cancer patients for year 2017

Category of hospital	Name of the hospital
National Hospital	National hospital including Dental Institute - Colombo, National Hospital for Respiratory Diseases – Welisara, National Eye hospital
Teaching Hospitals	Lady Ridgeway Hospital, De Soysa Maternity Hospital, Castle Street Hospital for Women, Colombo South Teaching Hospital, Colombo North Teaching Hospital
District General Hospitals	Avissawella, Gampaha
Base Hospitals	Panadura, Horana, Mulleriyawa
Private Sector Hospitals	Asiri Central, Asiri Medical, Asiri Surgical, Durdans Hospital, Lanka Hospital
Armed Services Hospitals	Army Hospital, Navy Hospital, Police Hospital

b. Details from Divisional Death Registrars of the Colombo district

Details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form – 3. A total of 40 divisional death registrars have sent relevant details for the year 2017.

2.2 Coding of cancer incidence data

According to the instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer. The cancer registry staff of the NCCP coded the cancer incidence data.

2.3 Entering of cancer incidence data to the database

Cancer incidence data were entered into the CanReg5 database by the trained data entry operators attached to the NCCP and also by a third party of data entry operators in a private company through a WHO funded project. These activities were closely supervised by the cancer registry staff and was regularly involved in refresher training to the data entry operators to ensure accuracy and quality of data.

2.4 Duplicate checking & verification of data

While entering and confirming the data to the CanReg5 database, duplicate checking was conducted using ‘Person search’ option of the CanReg 5 database. In addition to the duplicate checking done through CanReg 5, further duplicate checking had to be conducted during the data verification stage as well to identify all possible duplicates.

The additional methods used were;

- i. Use of Linkpro software
- ii. Use of Excel software – Sorted according to the descending or ascending order of selected variables

No. of cancers reported before the elimination of duplicates in year 2017	41401
No. of cancers detected after elimination of duplicates in year 2017	32170
Ratio of no. of reported cancers per incident cancer	1.3

After removing possible duplicates, consistency checking and verification was conducted using ‘IARCCrg’ tool & MS Excel.

Mismatches according to;

- Age / Incidence and birthdates
- Age / Site / Histology
- Site / Histology
- Sex / Site
- Sex / Histology
- Behaviour / Site
- Behaviour / Histology
- Grade / Histology Basis of Diagnosis / Histology were corrected.

After these procedures, preliminary analysis was conducted using CanReg 5 & SPSS to detect further mismatches. Data sources up to the patient clinic files were rechecked in the instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.5 Analysis of cancer incidence data & dissemination of information

Analysis section of the CanReg 5 package ('Frequency Distributions', 'Table Builder'), SPSS and MS Excel software were used to analyze cancer incidence data. The standard cancer registry tables described at the Cancer Incidence in 5 continents (CI 5) were generated through CanReg 5 database.

- Number of cancers by five-year age group and ICD 10 site among Males in Sri Lanka, 2017
- Number of cancers by five-year age group and ICD 10 site among Females in Sri Lanka, 2017
- Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100,000 population & Cumulative risk of cancers by five-year age group and ICD 10 site among Males in Sri Lanka, 2017

- Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100,000 population & Cumulative risk of cancers by five-year age group and ICD 10 site among Females in Sri Lanka, 2017

Population estimates used for incidence rates calculations are given at the table (v)

Table (V) Estimated mid-year population by district in Sri Lanka 2017

District	Male	Female	Total
Colombo	1186691	1231854	2418545
Gampaha	1158701	1232408	2391109
Kalutara	615177	656148	1271325
Kandy	692245	759591	1451836
Matale	248018	266293	514311
NuwaraEliya	361684	394575	756259
Galle	533884	579461	1113345
Matara	407763	443574	851337
Hambanthota	317626	328867	646493
Jaffna	285458	322457	607915
Mannar	54020	53441	107461
Vavuniya	90783	93661	184444
Mullaitivu	47488	47961	95749
Kilinochchi	61062	63189	124251
Batticaloa	266493	293300	559793
Ampara	341253	363723	704976
Trincomalee	203686	208681	412367
Kurunegala	813352	880394	1693746
Puttalam	393862	419965	813827
Anuradhapura	448010	469738	917748
Polonnaruwa	213054	217859	430913
Badulla	415157	448532	863689
Monaragala	240877	243802	484679
Ratnapura	567680	583771	1151451
Kegalle	418048	458733	876781
Total	10382072	11061978	21444350

Source – Department of Census & Statistics

2.6 Analysis of cancer mortality data

Cancer mortality data are received through two sources at national level.

- (i) Hospital Indoor Morbidity & Mortality Return of Medical Statistics Unit of Ministry of Health
- (ii) Cause Specific Death data published by the Department of Census & Statistics

Cancer mortality data received through the hospital Indoor Morbidity & Mortality Return are aggregated by the Medical Statistics Unit of the Ministry of Health and published at the Annual Health Bulletin of the Ministry of Health. Those summary reports related to the deaths due to cancers published at the Annual Health Bulletin was considered for the analysis.

According to the Births and Deaths Registration Act No. 17 of 1951 and its amendments, all deaths happened in hospitals or at home need to be registered at the respective Registrar within 5 days of the date of death. Therefore, all the deaths are registered at the vital registration system in the country. The aggregated data with cause of death are published by the Registrar General Department through its publication named 'Vital Statistics' and web site of the Department of Census and Statistics. Those available published data are further analyzed to generate specific information related to the cancer mortality. Since cause specific mortality data of year 2017 is not published yet, cancer mortality statistics for year 2017 is not available currently.

Cancer Incidence Data of Sri Lanka – 2017




Figure 1: Population pyramid of Sri Lanka in 2017 by 5-year age groups

Table 1: Cancer Incidence by sex in Sri Lanka, 2005- 2017

Year	Sex	Number	%	CR	ASR
2005	Male	6058	45.3	62.3	68.1
	Female	7314	54.7	73.4	73.4
	Total	13372		67.9	70.6
2006	Male	6205	44.1	62.7	69.2
	Female	7875	55.9	79	79.5
	Total	14080		70.9	74.2
2007	Male	6356	46.6	63.8	70.9
	Female	7279	53.4	72.2	72.8
	Total	13635		68	71.6
2008	Male	7695	46.6	76.5	85.5
	Female	8816	53.4	86.6	88
	Total	16511		81.6	86.4
2009	Male	7858	46.5	77.4	86.4
	Female	9030	53.5	87.7	89.1
	Total	16888		82.6	87.5
2010	Male	7993	47.1	78	87.4
	Female	8970	52.9	86.2	87.7
	Total	16963		82.1	87.3
2011	Male	8370	47.9	80.6	90.4
	Female	9112	52.1	86.7	88.7
	Total	17482		83.7	89.2
2012	Male	11363	49.1	115.3	107.8
	Female	11773	50.9	112.1	95.5
	Total	23136		113.6	100.1
2013	Male	11364	48.3	114	106.3
	Female	12167	51.7	114.6	97.4
	Total	23531		114.3	100.7
2014	Male	12021	47.6	119.5	112
	Female	13250	52.4	123.6	105.3
	Total	25271		121.6	107.3
2015	Male	13921	48.1	137.1	128.6
	Female	15046	51.9	139.1	118.8
	Total	28967		138.1	122
2016	Male	16533	48.4	161.1	151.2
	Female	17646	51.6	161.3	137.4
	Total	34179		161.2	142
2017	Male	15458	48.1	148.9	140.2
	Female	16712	51.9	151.1	128.8
	Total	32170		150	132.7




Figure 2: Crude Cancer Incidence Rates of Sri Lanka, 2005-2017




Figure 3: Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2017




Figure 4: Cancer Incidence Rates of Sri Lanka in 2017

Table 2: Cancer Incidence by 5-year age groups and sex in Sri Lanka 2017

Age Group	Male			Female			Total		
	Cases	Population	Incidence	Cases	Population	Incidence	Cases	Population	Incidence
Unknown	55			31			86		
00-04	153	927284	16.5	126	911904	13.8	279	1839188	15.2
05-09	80	929982	8.6	55	912664	6.0	135	1842646	7.3
10-14	94	873968	10.8	87	854984	10.2	181	1728952	10.5
15-19	122	864163	14.1	145	868985	16.7	267	1733148	15.4
20-24	132	781763	16.9	215	832792	25.8	347	1614555	21.5
25-29	187	783156	23.9	309	852733	36.2	496	1635890	30.3
30-34	245	839276	29.2	529	887514	59.6	774	1726790	44.8
35-39	373	722434	51.6	914	761392	120.0	1287	1483827	86.7
40-44	468	696615	67.2	1117	734437	152.1	1585	1431052	110.8
45-49	946	650971	145.3	1524	703046	216.8	2470	1354017	182.4
50-54	1552	612094	253.6	1821	671802	271.1	3373	1283895	262.7
55-59	1985	527286	376.5	2134	592875	359.9	4119	1120160	367.7
60-64	2356	447659	526.3	2183	518026	421.4	4539	965685	470.0
65-69	2569	298390	861.0	2182	367417	593.9	4751	665807	713.6
70-74	2048	191216	1071.0	1690	242320	697.4	3738	433536	862.2
75+	2093	236114	886.4	1650	349088	472.7	3743	585202	639.6
Total	15458	10382372	148.9	16712	11061978	151.1	32170	21444350	150.0




Figure 5: Age Specific Cancer Incidence Rates in Sri Lanka 2017

Table 3: Leading cancer site by sex in Sri Lanka – 2017

Male					Female				
ICD 10	Site	No	CR	ASR	ICD 10	Site	No	CR	ASR
C00-C06	Lip, Tongue & Mouth	2249	21.7	20	C50	Breast	4193	37.9	32.1
C33-C34	Trachea, Bronchus & Lung	1338	12.9	12.1	C73	Thyroid	2014	18.2	16.1
C18-C20	Colon & Rectum	1289	12.4	11.7	C18-C20	Colon & Rectum	1333	12.1	9.9
C15	Oesophagus	1167	11.2	10.4	C53	Cervix uteri	1071	9.7	8.1
C61	Prostate	1070	10.3	9.9	C56	Ovary	1065	9.6	8.3
C09-C14	Pharynx	854	8.2	7.6	C54-C55	Uterus	1008	9.1	7.6
C32	Larynx	737	7.1	6.6	C15	Oesophagus	843	7.6	6.1
C67	Bladder	678	6.5	6.2	C00-C06	Lip, Tongue & Mouth	587	5.3	4.4
C81-C85 & C96	Lymphoma	665	6.4	6.1	C33-C34	Trachea, Bronchus & Lung	468	4.2	3.6
C16	Stomach	525	5.1	4.7	C81-C85 & C96	Lymphoma	465	4.2	3.7
All sites		15458	148.9	140.2	All sites		16712	151.1	128.8




Figure 6: Proportion of leading cancers in males in Sri Lanka - 2017




Figure 7: Proportion of leading cancers in females in Sri Lanka - 2017

Crude incidence rates of leading cancers in Sri Lanka in 2017




Figure 8: Crude incidence rates of leading cancers in males in Sri Lanka - 2017




Figure 9: Crude incidence rates of leading cancers in females in Sri Lanka - 2017

Leading cancers of Sri Lanka according to age group in 2017




Figure 10: Leading cancers by 0-14 year age group among males in Sri Lanka in 2017




Figure 11: Leading cancers by 0-14 year age group among females in Sri Lanka in 2017




Figure 12: Leading cancers by 15 -34 year age group among males in Sri Lanka in 2017




Figure 13: Leading cancers by 15 -34 year age group among females in Sri Lanka in 2017




Figure 14: Leading cancers by 35 - 49 year age group among males in Sri Lanka in 2017




Figure 15: Leading cancers by 35 - 49 year age group among females in Sri Lanka in 2017




Figure 16: Leading cancers by 50 - 64 year age group among males in Sri Lanka in 2017




Figure 17: Leading cancers by 50 - 64 year age group among females in Sri Lanka in 2017




Figure 18: Leading cancers by 65 years & above age group among males in Sri Lanka in 2017




Figure 19: Leading cancers by 65 years & above age group among females in Sri Lanka in 2017

Table 4: Number of cancers by five – year age groups and ICD 10 site, among males in Sri Lanka in 2017

ICD 10 site	00- 04	05- 09	10- 14	15- 19	20- 24	25- 29	30- 34	35- 39	40- 44	45- 49	50- 54	55- 59	60- 64	65- 69	70- 74	75+ Unkn own	Total		
C00 Lip	0	0	0	0	0	0	1	0	3	1	14	14	15	16	6	7	2	79	
C01 Base of tongue	0	0	1	0	0	1	0	8	14	17	29	45	36	36	24	12	1	224	
C02 Other and unspecified parts of tongue	0	0	0	0	0	2	3	19	41	63	91	130	94	92	44	41	0	620	
C03 Gum	0	0	0	0	0	1	0	0	2	6	16	21	19	25	20	15	0	125	
C04 Floor of mouth	0	0	0	0	2	0	0	2	4	23	33	24	19	24	13	12	1	157	
C05 Palate	0	3	1	0	0	1	2	2	5	21	22	29	45	43	24	19	2	219	
C06 Other and unspecified parts of mouth	1	0	0	1	1	1	6	17	26	76	96	113	135	141	93	117	1	825	
C07 Parotid gland	0	0	1	1	4	7	1	4	5	3	6	5	11	12	8	7	1	76	
C08 Other and unspecified major salivary gland	0	0	0	0	1	0	0	1	3	1	3	3	9	0	2	2	0	25	
C09 Tonsil	0	0	0	0	0	0	0	4	6	26	42	38	35	34	16	19	1	221	
C10 Oropharynx	0	0	0	0	0	0	0	2	2	12	20	29	21	20	20	10	0	136	
C11 Nasopharynx	0	0	0	2	2	2	0	3	1	1	3	6	9	3	2	3	0	37	
C12 Pyriform sinus	0	0	0	0	0	0	0	0	4	14	39	35	34	33	29	25	1	214	
C13 Hypopharynx	0	0	0	0	0	0	0	1	0	1	5	17	23	26	21	30	21	0	145
C14 Other and ill-defined sites	1	0	0	0	0	0	0	0	2	13	10	15	18	15	17	10	0	101	
C15 Oesophagus	0	0	0	0	0	0	2	4	7	18	61	153	189	202	204	175	148	4	1167
C16 Stomach	0	0	0	3	0	2	6	10	11	33	46	81	98	98	66	68	3	525	
C17 Small intestine	0	2	0	0	0	0	0	1	3	3	9	13	10	11	5	5	1	63	
C18 Colon	0	1	2	5	4	3	7	12	25	42	55	59	71	99	83	102	0	570	
C19 Rectosigmoid junction	0	0	0	0	0	0	0	5	1	3	6	10	18	20	15	17	0	95	
C20 Rectum	0	0	0	0	0	5	5	12	11	35	59	77	91	110	108	109	2	624	
C21 Anus and anal canal	0	0	0	0	0	0	0	0	1	3	11	11	9	9	17	13	0	74	
C22 Liver and intrahepatic bile duct	8	2	0	3	0	0	1	4	3	9	28	41	61	67	60	47	1	335	

Table 4 continued ...

ICD 10 site	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	Unkn own	Total
	04	09	14	19	24	29	34	39	44	49	54	59	64	69	74			
C23 Gall bladder	0	0	0	0	0	0	0	1	5	0	3	5	1	7	3	5	0	30
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	0	1	1	3	7	6	9	8	7	6	6	0	54
C25 Pancreas	0	0	0	0	0	0	1	5	1	11	6	21	14	20	11	14	0	104
C26 Other and ill-defined digestive organs	1	0	0	1	0	0	0	1	2	0	5	0	3	3	5	2	0	23
C30 Nasal cavity and middle ear	0	0	2	0	2	0	3	3	2	1	6	6	7	6	2	3	1	44
C31 Accessory sinuses	0	0	1	0	2	0	0	0	2	1	2	4	1	7	2	3	0	25
C32 Larynx	0	0	0	0	1	0	3	3	4	45	96	130	124	136	99	94	2	737
C33 Trachea	0	0	0	0	0	1	0	0	0	4	4	1	3	6	0	0	0	19
C34 Bronchus and Lung	0	0	0	0	3	5	11	13	28	57	140	187	239	271	204	152	9	1319
C37 Thymus	0	0	0	0	0	1	2	1	1	5	2	1	0	3	2	0	1	19
C38 Heart, mediastinum and pleura	1	3	2	2	0	6	3	2	0	0	2	4	5	8	5	5	0	48
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	0	0	0	0	0	0	0	0	0	1	0	2	7	4	6	6	0	26
C40 Bone and articular cartilage of limbs	1	4	8	22	6	6	3	6	2	2	5	3	6	2	3	3	0	82
C41 Bone and articular cartilage of other and unspecified sites	1	2	4	8	3	5	7	2	2	3	2	3	0	5	2	1	0	50
C43 Melanoma of skin	0	0	0	0	0	2	0	1	0	0	5	5	3	13	7	9	0	45
C44 Other malignant neoplasms of skin	1	0	1	3	3	4	8	8	13	21	42	54	71	57	54	76	1	417
C45 Mesothelioma	0	0	0	0	0	0	0	0	0	0	1	0	3	0	0	1	5	
C47 Peripheral nerves and autonomic nervous system	1	1	0	0	0	0	1	0	1	1	0	3	1	3	4	1	0	17

Table 4 continued ...

ICD 10 site	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	Unkn own	Total
	04	09	14	19	24	29	34	39	44	49	54	59	64	69	74	1	0	25
C48	2	0	0	0	0	2	3	1	2	0	2	4	5	1	2	1	0	133
Retroperitoneum and peritoneum																		
C49 Connective, subcutaneous and other soft tissues	12	2	8	8	4	4	3	10	5	9	9	11	12	8	9	19	0	143
C50 Breast	0	0	0	0	1	0	2	9	8	8	9	31	22	28	14	11	0	121
C60 Penis	2	0	0	0	0	0	0	11	5	17	14	12	12	20	15	13	0	1070
C61 Prostate gland	0	0	0	0	0	1	3	2	2	7	24	47	130	255	246	346	7	132
C62 Testis	3	0	0	5	9	7	14	10	6	2	2	8	2	5	3	1	0	77
C63 Other and unspecified male genital organs	1	0	1	0	0	0	1	0	0	1	0	1	3	1	1	3	0	13
C64 Kidney	12	2	1	0	2	0	8	8	8	29	43	38	46	53	30	32	0	312
C65 Renal pelvis	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2
C66 Ureter	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	1	6
C67 Bladder	1	1	0	1	2	3	5	8	13	31	41	64	105	130	119	149	5	678
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	1	0	5
C69 Eye and adenexa	16	0	0	0	0	0	0	1	2	0	1	2	0	4	3	0	4	33
C70 Meninges	0	0	0	0	1	1	0	2	1	1	2	1	3	3	0	2	0	17
C71 Brain	12	15	9	6	8	13	23	18	19	25	17	32	29	24	16	4	1	271
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	0	0	0	0	1	1	1	2	1	0	0	0	2	0	0	8
C73 Thyroid gland	0	0	6	5	23	37	56	52	55	44	51	29	47	31	22	13	2	473
C74 Adrenal gland	9	3	0	0	0	0	1	1	1	2	2	0	2	0	1	1	0	23
C75 Other endocrine glands and related structures	0	0	0	0	0	0	0	1	0	2	0	0	1	2	0	0	0	6
C76 Other and ill- defined sites	3	0	0	0	1	1	0	1	0	1	3	6	5	9	7	8	0	45

Table 4 continued ...

ICD 10 site	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	Unkn	Total
	04	09	14	19	24	29	34	39	44	49	54	59	64	69	74	6	0	44
C77 Secondary and unspecified malignant neoplasm of lymph nodes	1	0	0	2	0	0	3	2	2	1	2	6	5	8	6	6	0	44
C80 Unknown primary	4	3	1	1	6	6	3	23	28	62	102	122	168	140	112	114	1	896
C81 Hodgkin disease	3	3	7	6	13	18	5	9	9	12	10	5	13	8	8	7	0	136
C82 Follicular (nodular) non-Hodgkin lymphoma	0	0	0	0	0	3	3	1	4	8	4	5	9	3	6	4	0	50
C83 Diffuse non-Hodgkin lymphoma	0	4	0	1	0	5	5	3	4	2	6	10	6	8	12	7	0	73
C84 Peripheral and cutaneous T-cell lymphoma	0	2	2	2	0	2	0	0	0	2	3	4	2	2	1	2	1	25
C85 Other and unspecified types of non-Hodgkin lymphoma	1	2	5	8	8	12	12	7	12	13	24	45	62	50	63	51	0	375
C88 immunoproliferative diseases	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	3
C90 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0	0	1	0	5	11	14	26	29	35	38	35	1	195
C91 Lymphoid leukaemia	42	22	25	18	8	3	5	8	6	8	9	8	10	12	7	15	0	206
C92 Myeloid leukaemia	7	2	5	6	11	9	4	16	10	11	16	13	31	31	13	26	0	211
C93 Monocytic leukaemia	0	1	0	0	0	0	0	1	0	1	0	1	0	1	1	2	0	8
C94 Other leukaemia of specified cell type	1	0	0	0	0	0	1	0	0	0	1	0	1	1	1	0	0	6
C95 Leukaemia of unspecified type	1	0	0	1	0	1	0	2	1	0	0	0	1	3	0	1	0	11

Table 4 continued ...

ICD 10 site	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	Unkn own	Total
	04	09	14	19	24	29	34	39	44	49	54	59	64	69	74	0	0	6
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	2	0	0	1	0	1	0	0	0	0	0	0	1	0	1	0	0	6
D45 Polycythemia vera	0	0	0	0	0	0	2	2	1	1	0	0	0	1	0	0	0	7
D46 Myelodysplastic syndromes	1	0	1	0	0	0	0	0	0	1	1	3	2	0	0	4	0	13
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	0	0	0	0	0	1	0	2	1	0	1	2	2	1	0	1	0	11
Total	153	80	94	122	132	187	245	373	468	946	1552	1985	2356	2569	2048	2093	55	15458

Table 5: Number of cancers by five – year age groups and ICD 10 site, among females in Sri Lanka in 2017

ICD 10 site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total	
C00 Lip	0	0	1	0	0	0	0	0	1	1	3	5	4	3	2	4	0	24	
C01 Base of tongue	0	0	0	0	0	0	0	2	3	1	1	9	7	5	10	5	0	43	
C02 Other and unspecified parts of tongue	0	0	0	1	1	2	1	14	10	11	21	17	21	13	18	12	1	143	
C03 Gum	0	1	0	0	0	0	2	2	1	1	7	3	6	10	8	11	1	53	
C04 Floor of mouth	0	0	0	0	0	0	1	0	1	0	2	7	3	4	1	3	0	22	
C05 Other and unspecified parts of mouth	0	1	1	0	0	0	1	1	2	1	7	8	6	13	10	10	0	61	
C06 Other and unspecified parts of mouth	0	0	0	0	0	0	4	6	3	10	12	24	41	54	43	43	1	241	
C07 Parotid gland	1	0	2	4	1	2	0	5	4	2	6	7	6	3	4	3	0	50	
C08 Other and unspecified major salivary gland	0	0	0	0	2	2	0	1	2	2	0	1	3	0	1	0	0	14	
C09 Tonsil	0	0	0	0	0	0	0	2	2	3	1	7	11	3	1	5	0	35	
C10 Oropharynx	0	0	0	0	0	0	0	0	1	2	0	1	1	4	1	2	0	12	
C11 Nasopharynx	0	0	0	2	1	2	1	0	2	1	2	0	3	3	3	0	0	20	
C12 Pyriform sinus	0	0	0	0	0	0	1	0	1	1	1	3	5	7	4	7	0	30	
C13 Hypopharynx	0	0	0	0	0	0	0	0	1	0	4	2	4	4	10	4	4	0	33
C14 Other and ill-defined sites	0	0	0	0	0	0	0	0	0	0	2	3	4	3	8	6	0	26	
C15 Oesophagus	0	0	0	0	0	0	1	1	8	10	20	53	89	147	165	148	195	6	843
C16 Stomach	0	0	0	0	0	1	3	3	6	6	11	27	22	37	46	33	24	0	219
C17 Small Intestine	0	0	0	0	0	0	0	0	1	1	7	4	10	7	10	2	6	0	48
C18 Colon	0	0	0	1	3	6	10	17	35	42	67	83	88	97	89	107	3	648	
C19 Rectosigmoid junction	0	0	0	0	0	0	0	2	2	3	13	12	11	16	17	11	0	87	
C20 Rectum	0	0	0	0	0	0	4	9	11	21	35	66	84	103	89	76	100	0	598
C21 Anus and anal canal	0	0	0	0	0	0	0	0	1	1	0	3	3	8	10	13	10	0	49
C22 Liver and intrahepatic bile duct	4	1	1	0	0	3	1	2	8	7	8	16	11	25	26	20	0	133	
C23 Gall bladder	0	0	0	0	0	0	1	0	2	2	1	5	6	4	11	6	8	0	46
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	0	0	0	1	5	8	11	12	8	8	7	0	60	

Table 5 continued ...

ICD 10 site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total	
C25 Pancreas	0	1	0	1	3	1	1	2	7	6	17	9	10	15	17	11	0	101	
C26 Other and ill-defined digestive organs	0	0	0	0	0	0	0	1	2	0	5	1	4	2	1	7	0	23	
C30 Nasal cavity and middle ear	0	0	0	1	0	1	4	4	7	4	2	3	11	6	4	3	0	50	
C31 Accessory sinuses	0	0	0	0	0	0	0	0	0	2	0	1	3	2	3	2	0	13	
C32 Larynx	0	0	0	0	0	0	0	0	0	5	10	9	8	10	10	21	0	73	
C33 Trachea	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	3	
C34 Bronchus and lung	0	0	1	0	0	3	6	14	22	40	49	52	88	82	63	45	0	465	
C37 Thymus	0	0	0	0	0	1	0	2	2	3	6	1	2	1	1	1	0	20	
C38 Heart, mediastinum and pleura	3	2	1	1	2	0	1	0	3	0	2	3	7	6	4	4	0	39	
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	0	0	0	0	0	0	0	0	1	3	0	1	5	1	0	1	0	12	
C40 Bone and articular cartilage of limbs	0	2	16	7	2	4	3	2	2	2	0	0	2	0	2	0	0	44	
C41 Bone and articular cartilage of other and unspecified sites	1	2	5	1	7	2	0	5	2	2	2	5	1	0	3	5	0	43	
C43 Melanoma of skin	0	0	0	1	1	0	0	0	0	3	0	2	5	6	5	15	0	38	
C44 Other malignant neoplasms of skin	0	0	0	1	4	4	5	9	9	13	17	32	37	34	58	66	1	290	
C45 Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	
C47 Peripheral nerves and autonomic nervous system	3	1	0	0	2	0	1	2	0	0	2	2	1	0	1	1	0	16	
C48 Retropertitoneum and peritoneum	3	0	0	0	0	0	0	4	1	0	4	4	7	2	4	1	3	33	
C49 Connective, subcutaneous and other soft tissues	5	2	7	5	1	8	6	7	10	10	12	20	9	8	13	6	0	129	
C50 Breast	1	0	0	1	9	31	111	262	373	582	576	592	580	458	341	270	6	4193	
C51 Vulva	0	0	0	0	0	0	1	0	1	5	7	3	3	9	14	11	0	54	
C52 Vagina	0	0	0	0	1	1	0	0	2	5	3	12	8	11	1	13	0	57	
C53 Cervix uteri	0	0	0	0	0	0	6	36	71	104	132	179	145	158	121	117	2	1071	
C54 Corpus uteri	0	0	0	0	0	2	1	3	16	29	39	91	126	125	129	71	51	683	
C55 Uterus not specified	0	0	0	0	0	0	2	3	4	17	23	44	61	58	53	35	25	0	325

Table 5 continued ...

ICD 10 site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total
C56 Ovary	2	5	5	35	17	20	32	47	58	82	143	164	153	157	75	69	1	1065
C57 Other and unspecified female genital organs	0	1	2	1	0	2	0	0	1	5	1	3	4	6	2	1	0	29
C58 Placenta	0	0	0	0	1	0	4	0	0	0	0	0	0	0	0	0	0	5
C64 Kidney	17	3	1	1	0	1	3	2	7	10	17	16	15	20	14	12	0	139
C65 Renal pelvis	0	0	0	1	0	0	0	0	0	0	1	1	1	0	1	1	0	6
C66 Ureter	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	4
C67 Bladder	1	0	0	0	1	0	1	0	3	9	14	24	21	28	30	38	1	171
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2
C69 Eye and adenexa	18	3	0	0	0	0	0	0	1	1	0	0	1	2	0	0	2	28
C70 Meninges	0	0	0	0	1	2	1	4	2	3	2	2	0	4	2	0	0	23
C71 Brain	9	9	7	4	3	4	13	19	9	16	14	22	12	17	6	7	0	171
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	3
C73 Thyroid gland	2	1	9	42	118	145	227	315	280	267	139	150	117	95	57	46	4	2014
C74 Adrenal gland	6	1	1	0	0	1	1	3	0	1	0	0	1	1	0	1	1	18
C75 Other endocrine glands and related structures	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	5
C76 Other and ill-defined sites	1	0	0	0	1	1	0	1	1	1	8	5	5	4	12	4	0	44
C77 Secondary and unspecified malignant neoplasm of lymph nodes	0	0	0	0	0	0	0	0	1	1	2	3	4	5	3	2	0	21
C80 Unknown primary	4	1	2	4	2	11	8	21	33	39	84	89	75	100	74	75	2	624
C81 Hodgkin disease	0	3	3	14	10	21	13	4	4	0	10	7	4	6	3	2	0	104
C82 Follicular (nodular) Non Hodgkin lymphoma	1	0	0	0	0	0	1	0	1	3	9	3	6	3	5	1	0	33
C83 Diffuse Non Hodgkin lymphoma	1	2	1	1	0	2	6	2	2	2	4	7	2	8	9	7	0	56
C84 Peripheral and cutaneous T-cell lymphoma	0	0	1	0	2	0	0	2	0	1	0	2	2	0	1	2	0	13
C85 Other and unspecified types of Non Hodgkin lymphoma	0	0	2	3	5	7	11	12	7	19	28	26	27	44	25	38	0	254
C88 Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2

Table 5 continued ...

ICD 10 site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total
C90 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0	0	1	1	3	9	14	24	28	38	25	25	0	168
C91 Lymphoid leukaemia	33	12	13	7	2	1	6	7	6	2	4	4	9	8	6	8	0	128
C92 Myeloid leukaemia	5	0	4	5	8	6	8	13	14	23	17	20	25	26	24	21	1	220
C93 Monocytic leukaemia	1	0	0	0	0	0	0	0	0	1	3	0	0	2	1	1	0	9
C94 Other leukaemia of specified cell type	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	5
C95 Leukaemia of unspecified type	0	0	1	0	1	0	1	1	1	2	0	0	1	0	0	2	0	10
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	2	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	5
D45 Polycythaemia vera	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	4
D46 Myelodysplastic syndromes	0	0	0	0	0	0	0	1	4	1	0	0	1	0	1	4	1	0
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	2
Total	126	55	87	145	215	309	529	914	1117	1524	1821	2134	2183	2182	1690	1650	31	16712

Table 6: Number of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka 2017

Cancer Registry (2017)

Year 2017

Cases by age group (Period) - Male

SITE	ALL AGE AGES UNK	0-5	10-15	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (Total)		
Lip	79	2	1	1	1	1	1	1	1	1	1	14	14	15	16	7	0.5	C00	
Tongue	844	1	3	1	1	1	3	3	27	55	80	120	175	130	68	53	5.6	C01-C02	
Mouth	1326	4	1	1	1	1	3	8	21	37	126	167	218	233	150	163	8.8	C03-C06	
Salivary glands	101	1	1	1	1	1	5	1	5	8	4	9	8	12	10	9	0.7	C07-C08	
Tonsil	221	1	1	1	1	1	1	1	4	6	26	42	38	35	34	19	1.5	C09	
Other oropharynx	136	0	1	1	1	1	2	2	2	2	20	29	21	20	20	10	0.9	C10	
Nasopharynx	37	0	1	1	1	1	2	2	1	1	1	1	3	6	9	3	0.2	C11	
Hypopharynx	159	1	1	1	1	1	1	1	1	5	19	56	58	60	54	59	2.4	C12-C13	
Pharynx unspecified	101	0	1	1	1	1	1	1	1	2	13	10	15	18	15	17	0.7	C14	
Stomach	525	3	1	1	1	1	3	2	4	7	18	61	153	189	202	175	148	3.5	C15
Small intestine	63	1	1	1	1	1	2	6	10	11	33	46	81	98	66	68	3.5	C16	
Colon	570	0	2	1	2	1	5	4	3	7	12	25	42	55	59	71	5	0.4	C17
Rectum	719	2	1	1	1	1	5	5	17	12	38	65	87	109	130	123	3.8	C18	
Anus	74	0	1	1	1	1	1	1	1	1	1	11	11	9	9	17	1.3	C19-C20	
Liver	315	1	2	1	1	1	3	1	4	3	9	28	41	61	67	60	5.5	C21	
Gallbladder etc.	84	0	1	1	1	1	1	1	1	2	8	7	9	14	9	11	2.2	C22	
Pancreas	104	0	1	1	1	1	1	1	1	1	11	6	21	14	20	11	14	0.6	C23-C24
Nose, sinuses etc.	69	1	1	1	1	1	3	4	1	3	3	4	2	8	10	8	4	0.5	C25-C31
Larynx	737	2	1	1	1	1	3	6	11	13	28	61	144	188	242	277	204	4.9	C32
Trachea, bronchus and lung	1338	9	1	1	2	2	7	5	5	3	1	5	4	5	5	11	7	8.9	C33-C34
Other thoracic organs	67	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.4	C37-C38	
Bone	142	0	2	6	12	30	9	11	10	8	4	5	7	6	7	5	4	0.9	C40-C41
Melanoma of skin	45	0	1	1	1	1	1	1	1	1	1	1	1	5	5	3	1	0.3	C43
Other skin	417	1	1	1	1	1	3	3	4	8	8	13	21	42	54	71	57	2.8	C44
Mesothelioma	5	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C45	
Kaposi's sarcoma	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C46	
Connective and soft tissue	150	0	13	3	8	8	4	4	4	10	6	10	9	14	13	13	20	1.0	C47-C49
Breast	143	0	1	1	1	1	1	1	1	2	9	8	8	9	31	22	28	11	C50
Penis	121	0	2	1	1	1	1	1	1	1	11	5	17	14	12	12	15	1.3	C51
Prostate	1070	7	1	1	1	1	1	1	1	1	2	7	24	47	130	255	246	7.1	C56
Testis	77	0	3	1	1	1	3	9	1	1	10	6	2	2	8	2	3	0.5	C57
Other male genital organs	13	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.1	C63
Kidney	312	0	12	2	1	1	2	1	1	1	1	1	1	1	1	1	1	2.1	C64
Renal pelvis	2	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C65
Urter	6	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C66
Bladder	678	5	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4.5	C67
Other urinary organs	5	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C68
Eye	33	0	16	12	7	6	9	14	14	2	2	2	2	2	4	4	0.2	C69	
Brain, nervous system	296	1	12	7	5	6	9	14	26	21	27	28	20	33	32	27	18	2.0	C70-C72
Thyroid	473	2	9	3	6	5	23	37	56	52	55	44	51	29	47	31	22	3.1	C73
Adrenal gland	23	0	9	3	1	1	1	1	1	1	1	2	2	2	2	1	1	0.2	C74
Other endocrine	6	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C75
Hodgkin disease	136	0	3	3	2	2	6	13	18	5	9	9	12	10	4	3	7	0.9	C76
Non-Hodgkin lymphoma	529	0	3	3	8	7	12	8	23	20	11	25	37	64	80	63	64	3.5	C77-C86
Multiple myeloma	193	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.0	C89
Lymphoid leukaemia	206	0	42	22	25	18	8	3	5	8	6	8	9	10	12	7	15	1.4	C91
Myeloid leukaemia	225	0	8	5	6	11	9	5	17	10	12	14	17	14	12	3	15	1.5	C92-C94
Leukaemia unspecified	11	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.1	M65
Myelodysplastic disorders	13	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.1	MDS
Myelodysplastic syndromes	11	1	11	3	1	4	7	9	9	28	34	65	114	140	193	163	137	7.0	D&U
Other and unspecified	1059	1	133	80	94	122	132	187	245	373	468	946	1552	1985	2356	2569	2048	2093	All
All sites but C44	15438	55	152	80	93	119	129	183	237	365	455	925	1510	1931	2285	2512	1994	2017	100.0

Table built Mon Jul 19 16:00:34 IST 2021 by CutReg5

Table 7: Number of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka 2017

SITE	ALL AGE AGES UNK	0-5	5-10	10-15	15-20	20-25	25-30	30-35	35-40	40-45	45-50	50-55	55-60	60-65	65-70	70-75	(%)	ICD (I0/I0m)	
Lip	24	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.1	C00-C02	
Tongue	186	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1.1	C03-C06	
Mouth	377	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	2.3	C07-C08	
Salivary glands	64	0	1	2	4	3	4	6	6	6	6	6	8	9	3	3	0.4	C09	
Tonsil	35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C10	
Other oropharynx	12	0	0	2	1	1	1	1	1	1	1	1	1	1	1	1	0.1	C11	
Nasopharynx	20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C12-C13	
Hypopharynx	63	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	C14	
Pharynx unspecified	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C15	
Oesophagus	843	6	0	0	0	0	0	1	1	1	1	1	1	1	1	1	5.1	C16	
Stomach	219	0	0	0	0	0	0	1	3	3	6	6	11	27	37	24	1.3	C17	
Small intestine	45	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	0.3	C18	
Colon	648	3	0	0	0	0	0	1	3	6	10	17	25	42	67	83	107	3.9	C19-C20
Rectum	685	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C21	
Anus	49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	C22	
Liver	133	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	C23-C24	
Gallbladder etc.	106	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	C25	
Pancreas	101	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	C26	
Nose, sinuses etc.	65	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	C27	
Larynx	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	C28-C34	
Trachea, bronchus and lung	468	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	C35-C38	
Other thoracic organs	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	C39-C41	
Bone	87	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	C42	
Melanoma of skin	38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C43	
Other skin	290	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.8	C44	
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C45	
Kaposi's sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C46	
Connective and soft tissue	145	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9	C47-C49	
Breast	4193	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	C50	
Vulva	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	C51	
Vagina	57	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	C52	
Cervix uteri	1071	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.5	C53	
Corpus uteri	683	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.2	C54	
Uterus unspecified	325	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.0	C55	
Ovary	1065	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	C56-C58	
Other female genital organs	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C59	
Placenta	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C60	
Kidney	139	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	C61	
Renal pelvis	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C62	
Ureter	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C63	
Bladder	177	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.9	C64	
Other urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C65	
Eye	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C66	
Brain, nervous system	197	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.2	C67-C72	
Thyroid	2014	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C73	
Adrenal gland	18	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C74	
Other endocrine	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C75	
Hodgkin disease	104	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C76	
No-Hodgkin lymphoma	361	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C77	
Immunoproliferative diseases	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C78	
Multiple myeloma	168	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C79	
Lymphoid leukaemia	128	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C80	
Myleoid leukaemia	234	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C81	
Leukaemia unspecified	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C82-C84	
Myeloproliferative disorders	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C85	
Myelodysplastic syndromes	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	MPD	
Other and unspecified	757	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	MDS	
All sites	16712	31	126	55	87	144	211	305	524	905	108	1511	1804	2146	2146	1632	4.6	All	
All sites but C44	16422	30	126	55	87	144	211	305	524	905	108	1511	1804	2146	2146	1632	100.0	All but C44	

Table builtMon Jul 19 16:00:54 IST 2021 by CanReg5.

Table 8: Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka, 2017

Cancer Registry (2017)

Year 2017

Incidence per 100,000 by age group (Period) - Male

SITE	ALL AGES	0-4	5-10	10-15	15-20	20-25	25-30	30-35	35-40	40-45	45-50	50-55	55-60	60-65	65-70	70-75	75+	CRUDE RATE (%)	CUM (%)	CUM (%)	ASR	ICD (200)		
	AGES UNK																		D44	D44	D44	0-74		
Lip	79	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.8	0.5	0.5	0.8	C07		
Tongue	844	1	0.1	0.3	0.1	0.1	0.1	0.4	0.4	0.4	0.4	0.2	0.2	0.3	0.3	0.4	0.4	0.5	0.5	0.5	0.5	C07-02		
Mouth	1326	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.1	5.6	5.3	0.93	C07-06		
Salivary glands	101	-	-	-	-	-	-	-	0.1	0.7	1.1	0.6	1.5	1.5	4.5	4.0	1.0	0.7	0.6	1.0	1.19	C07-08		
Tonsil	221	1	-	-	-	-	-	-	-	-	-	0.6	0.9	4.0	4.0	5.2	3.8	2.1	1.5	1.4	0.24	1.9	C09	
Other oropharynx	136	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.3	0.9	0.6	0.17	C10		
Nasopharynx	37	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	0.2	0.1	0.04	C11		
Hypopharynx	359	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.5	2.4	1.9	0.43	C12-13		
Pharynx unspecified	101	0	-	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-	1.0	0.7	0.5	0.12	0.9	C14	
Oesophagus	1167	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.12	7.8	8.0	1.40	10.5	C15	
Stomach	525	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.1	3.5	2.7	0.61	4.7	C16	
Small intestine	63	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	0.4	0.3	0.07	0.6	C17	
Colon	710	0	0.1	0.2	0.6	0.3	0.4	0.8	1.7	0.4	0.4	0.1	0.1	0.5	1.1	1.2	1.5	3.5	3.8	2.5	0.63	5.2	C18	
Rectum	719	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.6	24.3	43.4	64.3	179.20	C19-20	
Anus	74	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.8	2.0	3.0	8.9	2.7	C21	
Liver	355	1	0.9	0.2	-	-	-	-	-	-	-	-	-	-	-	-	-	22.5	31.4	31.4	3.2	4.2	C22	
Gallbladder etc.	84	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.1	1.5	2.2	0.15	3.1	C23-24	
Pancreas	104	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.7	0.8	0.6	0.04	0.7	C25	
Nose, sinuses etc.	69	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.0	0.7	0.05	0.12	0.9	C26	
Larynx	737	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.0	0.7	0.2	0.05	0.9	C27	
Trachea, bronchi and lung	1338	9	-	0.1	0.3	0.2	0.4	0.8	1.3	1.8	4.0	9.4	23.5	24.7	27.7	27.7	35.7	12.9	8.9	8.6	1.66	12.1	C28	
Other thoracic organs	67	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.9	1.1	3.7	2.1	0.6	C29	
Brain	132	0	-	0.2	0.6	1.4	3.5	1.2	1.4	1.2	1.1	0.6	0.8	1.1	1.1	1.3	2.3	2.6	1.7	1.3	0.9	0.08	0.10	C30-H1
Melanoma of skin	45	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.8	0.7	0.5	0.01	0.05	C49	
Other skin	477	7	-	0.7	-	0.1	0.3	0.4	0.5	1.0	1.2	1.9	3.2	3.2	3.2	3.2	3.2	4.0	3.1	0.2	0.45	3.7	C44	
Mesothelioma	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.0	0.01	0.0	C45	
Kaposi's sarcoma	150	0	-	-	1.4	0.3	0.9	0.5	0.3	0.5	1.4	0.9	0.9	0.1	0.1	0.1	0.1	0.0	0.4	0.4	0.0	0.0	C46	
Connective and soft tissue	143	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.3	0.5	1.3	0.1	0.01	C47-C49	
Breast	121	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.3	0.9	0.08	0.16	1.3	C50	
Panx	208	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.2	0.8	0.06	0.13	1.1	C60	
Prostate	1070	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.1	4.9	3.8	0.77	6.6	C61	
Testis	77	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0	C62	
Other male genital organs	13	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.7	0.5	0.5	0.06	0.7	C63	
Kidney	312	0	-	1.3	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.01	0.1	C64	
Renal pelvis	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0	C65	
Ureter	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.1	0.0	0.0	0.0	0.1	C66	
Bladder	678	5	-	-	-	0.1	-	-	-	-	-	-	-	-	-	-	-	6.5	4.3	2.6	0.79	6.2	C67	
Other urinary organs	5	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0	C68	
Eye	33	0	-	1.7	1.3	1.6	1.0	0.7	1.2	1.8	0.1	0.3	0.2	0.3	0.3	0.3	0.3	0.7	0.2	0.03	0.02	0.4	C69	
Brain, nervous system	296	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.5	2.0	1.7	0.28	2.7	C70-72	
Thyroid	473	2	0	1.0	0.3	-	-	-	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	1.3	0.9	0.08	0.12	1.3	C81	
Adrenal gland	23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.5	0.5	0.5	0.2	0.01	C73	
Other endocrine	6	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.1	0.0	0.0	0.0	0.1	C74	
Hodgkin disease	136	0	-	-	0.3	0.3	0.8	0.7	1.7	2.3	0.6	1.3	1.8	1.6	0.9	0.9	0.9	1.1	1.3	0.21	0.21	0.21	C75	
Non-Hodgkin lymphoma	529	-	0.9	0.3	0.8	0.8	0.7	1.0	2.9	2.4	1.5	2.9	3.8	6.0	1.2	1.2	1.2	1.1	1.1	1.1	1.1	1.1	C76/C77	
Immunoproliferative diseases	3	0	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.1	0.1	0.1	0.0	0.1	C78	
Multiple myeloma	195	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.1	0.1	0.1	0.0	0.1	C79	
Lymphoid leukaemia	206	0	-	4.5	2.4	2.9	2.1	1.0	0.4	0.6	1.1	0.6	1.2	1.5	2.2	4.0	3.7	6.4	2.0	1.4	0.11	0.15	C81	
Myeloid leukaemia	225	0	-	-	0.9	0.3	0.6	0.7	1.4	1.1	0.6	2.4	1.4	1.8	2.8	2.7	7.8	11.9	2.3	1.5	0.12	2.1	C82-C84	
Leukaemia unspecified	11	0	-	-	-	0.1	-	-	-	-	-	-	-	-	-	-	-	0.1	0.1	0.0	0.0	0.1	C85	
Myceloproliferative disorders	18	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.2	0.1	0.1	0.02	0.2	M8D	
Myelodysplastic syndromes	13	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.01	0.1	M8S	
Other and unspecified	1059	1	-	1.2	0.3	0.1	0.5	0.9	1.1	3.9	4.9	10.0	18.6	26.6	43.1	55.3	72.2	58.0	10.2	7.0	0.56	1.20	9.6	O&U
All sites	15438	35	165	8.6	10.8	14.1	16.9	23.9	29.2	51.6	67.2	143.3	253.6	376.5	526.3	861.0	1071.0	886.4	10.2	7.0	0.56	1.20	9.6	ALL
All sites but C44	15041	34	16.4	8.6	10.6	13.8	16.5	23.4	28.2	50.5	65.3	142.1	246.7	366.2	510.4	841.9	1042.8	854.2	14.4	9.1	0.56	1.20	9.6	ALL/C44

Table 9: Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka, 2017

Cancer Registry (2017)

Year 2017

Incidence per 100,000 by age group (Period) - Female

SITE	ALL AGE AGES UNK	0-5	10-15	20-25	30-35	40-45	50-55	60-65	70-75	75+	CRUDE RATE	CUM (%)	CUM ASR	ASR ICD (Rate)
Lip	24	0	-	0.1	0.1	0.1	0.1	0.4	0.8	0.8	0.2	0.1	0.01	0.2
Tongue	186	1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	1.7	1.1	0.10	1.4
Mouth	377	2	0.1	0.2	0.5	0.4	0.5	0.9	1.7	2.3	3.4	2.3	0.14	2.8
Salivary glands	64	0	-	-	-	-	-	-	-	-	0.6	0.4	0.04	0.5
Tonsil	35	0	-	-	-	-	-	0.3	0.4	0.1	0.1	0.1	0.02	0.3
Other oropharynx	12	0	-	-	-	-	-	0.3	0.3	0.3	0.2	0.2	0.03	0.3
Nasopharynx	20	0	-	-	-	-	-	0.8	1.0	1.7	0.8	2.1	0.9	2.3
Hypopharynx	63	0	-	-	-	-	-	0.6	0.9	1.3	0.4	0.4	0.04	0.5
Pharynx unspecified	26	0	-	-	-	-	-	0.3	0.4	0.1	0.1	0.1	0.02	0.3
Oesophagus	843	6	-	-	-	-	-	0.1	0.1	1.4	2.8	28.4	44.9	61.1
Stomach	219	0	-	-	-	-	-	0.1	0.3	0.8	1.6	4.0	3.7	7.1
Small intestine	48	0	-	-	-	-	-	0.1	0.1	0.1	0.2	0.2	0.1	0.2
Colon	648	3	-	-	-	-	-	0.1	0.2	0.8	1.0	1.4	1.2	1.7
Rectum	685	0	-	-	-	-	-	0.5	1.0	2.2	4.8	10.0	17.0	26.4
Amt	49	0	-	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.02	0.2
Liver	133	0	-	-	-	-	-	0.4	0.1	0.3	1.1	1.0	0.5	1.3
Gallbladder etc.	106	0	-	-	-	-	-	0.1	0.1	0.1	0.2	0.2	0.1	0.2
Pancreas	101	0	-	-	-	-	-	0.1	0.1	0.1	0.9	2.5	1.5	3.2
Nose, sinuses etc.	63	0	-	-	-	-	-	0.1	0.1	0.5	1.0	1.0	0.6	1.0
Larynx	73	0	-	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.02	0.4
Trachea, bronchus and lung	488	0	-	-	-	-	-	0.1	0.1	0.4	0.8	1.0	1.2	1.8
Other thoracic organs	59	0	-	-	-	-	-	0.3	0.1	0.2	0.1	0.1	0.01	0.2
Bone	87	0	-	-	-	-	-	0.1	0.4	0.1	0.1	0.1	0.01	0.1
Melanoma of skin	38	0	-	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.01	0.3
Other skin	296	1	-	-	-	-	-	0.1	0.1	0.1	0.1	0.1	0.01	0.5
Mesothelioma	1	0	-	-	-	-	-	-	-	-	-	-	-	0.1
Kaposi's sarcoma	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Connective and soft tissue	145	0	-	-	-	-	-	0.9	0.8	0.4	0.9	0.9	0.6	0.9
Breast	4,193	6	0.1	-	-	0.1	1.1	3.6	12.5	36.4	50.8	82.6	85.7	99.9
Vulva	34	0	-	-	-	-	0.1	0.1	0.1	0.1	0.7	1.0	0.5	2.4
Vagina	57	0	-	-	-	-	0.1	0.1	0.1	0.1	0.7	1.3	0.5	2.7
Cervix uteri	1,071	2	-	-	-	-	0.1	0.1	0.7	4.7	9.7	19.6	30.2	37.7
Corpus uteri	683	0	-	-	-	-	0.2	0.1	0.3	3.9	5.5	13.5	21.4	30.5
Uterus unspecified	325	0	-	-	-	-	0.2	0.3	0.3	2.3	3.3	6.5	10.3	14.6
Ovary	1,035	1	0.2	-	-	-	0.5	0.6	2.0	2.7	7.9	11.7	27.7	42.7
Other female genital organs	29	0	0.1	0.2	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.05	0.3
Placenta	3	0	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.2
Kidney	139	4	1.9	0.3	0.1	0.1	0.1	0.3	1.0	1.4	2.5	2.7	2.9	3.4
Kidney pelvis	6	0	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.4
Ureter	4	0	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.4
Bladder	177	4	0.7	-	-	-	-	-	-	-	0.1	0.1	0.01	0.2
Other urinary organs	2	0	-	-	-	-	-	-	-	-	-	-	-	-
Eye	28	0	2.0	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.4	0.6	0.9
Brain, nervous system	197	0	7.0	0.8	0.5	0.5	0.7	1.6	3.0	4.4	4.2	2.7	3.3	7.8
Thyroid	2014	4	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Adrenal gland	18	1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Other endocrine	5	0	-	-	-	-	-	-	-	-	-	-	-	-
Hodgkin disease	104	0	0.3	0.4	1.6	1.2	2.5	1.5	0.5	1.5	1.2	0.8	1.6	2.6
Non-Hodgkin lymphoma	361	0	0.4	0.3	0.5	0.8	1.1	2.0	2.1	3.6	6.3	6.4	7.1	15.2
Immunoproliferative diseases	2	0	-	-	-	-	-	-	-	-	0.2	0.2	0.1	0.2
Multiple myeloma	168	0	-	-	-	-	-	-	-	-	0.2	0.2	0.1	0.2
Lymphoid leukaemia	128	0	3.6	1.3	1.5	0.8	0.2	0.1	0.7	0.9	0.8	0.3	0.7	2.3
Myceloid leukaemia	234	1	0.9	0.5	0.6	0.1	0.1	0.7	0.1	1.1	3.4	3.1	4.8	11.1
Leukaemia unspecified	10	0	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.1
Metaproliferative disorders	6	0	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.1
Myelodysplastic syndromes	33	0	-	-	-	-	-	-	-	-	0.1	0.1	0.01	0.1
Other and unspecified	737	2	0.9	0.1	0.2	0.5	0.4	1.4	3.2	5.2	6.8	15.3	17.9	31.6
All sites but C44	16,712	31	13.8	6.0	10.2	16.7	25.8	36.2	39.6	120.0	152.1	246.8	359.9	697.4
All sites but C44	16,422	30	13.8	6.0	10.2	16.6	25.3	35.8	39.0	118.0	150.9	214.9	345.5	673.5

Reference population: World Standard Population

Table builtMast(Jul 19 16:03:57 IST 2021) by CanReg

Table 10: Lip, Tongue and Mouth cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	2249	14.5	20	2.50
Female	587	3.5	4.4	0.57

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C00.0 External upper lip		9	2
C00.1 External lower lip		19	9
C00.3 Mucosa of upper lip		0	1
C00.4 Mucosa of lower lip		4	0
C00.6 Commissure of lip		29	8
C00.8 Overlapping lesion of mouth		1	1
C00.9 Lip, NOS		17	3
C01.9 Base of tongue, NOS		224	43
C02.0 Dorsal surface of tongue		18	7
C02.1 Border of tongue		139	34
C02.2 Ventral surface of tongue		52	20
C02.3 Anterior 2/3 of tongue		1	1
C02.4 Lingual tonsil		1	0
C02.8 Overlapping lesion of tongue		3	2
C02.9 Tongue, NOS		406	79
C03.0 Upper gum		33	13
C03.1 Lower gum		44	21
C03.9 Gum, NOS		48	19
C04.0 Anterior floor of mouth		9	2
C04.1 Lateral floor of mouth		6	2
C04.9 Floor of mouth, NOS		142	18
C05.0 Hard palate		13	12
C05.1 Soft palate, NOS		126	15
C05.2 Uvula		9	2
C05.8 Overlapping lesion of palate		2	1
C05.9 Palate, NOS		69	31
C06.0 Cheek mucosa		550	174
C06.1 Vestibule of mouth		21	11
C06.2 Retromolar area		98	15
C06.8 Overlapping lesion of other/unspecified parts of mouth		32	3
C06.9 Mouth, NOS		124	38
Total		2249	587

ICD O Code and histology		Male	Female
8000 Neoplasm, malignant		100	30
8010 Carcinoma, NOS		12	4
8020 Carcinoma, undifferentiated, NOS		2	0
8022 Pleomorphic carcinoma		0	1
8032 Spindle cell carcinoma, NOS		2	1

Table 10 continued ...

ICD O Code and histology	Male	Female
8033 Pseudosarcomatous carcinoma	1	0
8050 Papillary carcinoma, NOS	4	1
8051 Verrucous carcinoma, NOS	53	5
8052 Papillary squamous cell carcinoma	1	2
8070 Squamous cell carcinoma, NOS	1956	475
8071 Squamous cell carcinoma, keratinizing, NOS	53	16
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	3	1
8076 Squamous cell carcinoma, microinvasive	4	1
8083 Basaloid squamous cell carcinoma	9	1
8120 Transitional cell carcinoma, NOS	2	0
8140 Adenocarcinoma, NOS	8	10
8200 Adenoid cystic carcinoma	13	18
8211 Tubular adenocarcinoma	1	0
8310 Clear cell adenocarcinoma, NOS	1	0
8430 Mucoepidermoid carcinoma	11	14
8480 Mucinous adenocarcinoma	1	0
8525 Polymorphous low-grade adenocarcinoma	0	2
8550 Acinar cell carcinoma	3	1
8560 Adenosquamous carcinoma	1	0
8720 Malignant melanoma, NOS (except juvenile melanoma M-8770/0)	3	1
8800 Sarcoma, NOS	1	0
8802 Giant cell sarcoma	0	1
8806 Desmoplastic small round cell tumour	0	2
8890 Leiomyosarcoma, NOS	1	0
8982 Malignant myoepithelioma	2	0
9580 Granular cell tumor, malignant	1	0
Total	2249	587




Figure 20: Age specific rates of Lip, Tongue & Mouth cancer in Sri Lanka in 2017




Figure 21: Age standardized incidence rates of Lip, Tongue & Mouth cancer in Sri Lanka, 2005- 2017

Table 11: Pharyngeal cancer incidence data in Sri Lanka, 2017

Group		Number	%	ASR	Cum. Rate
Male		854	5.5	7.6	0.99
Female		156	0.9	1.2	0.15

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code & site		Male	Female
C09.0	Tonsillar fossa	7	1
C09.1	Tonsillar pillar	10	1
C09.8	Overlapping lesion of tonsil	1	0
C09.9	Tonsil, NOS	203	33
C10.0	Vallecula	76	9
C10.1	Anterior surface of epiglottis	3	2
C10.2	Lateral wall of oropharynx	4	0
C10.3	Posterior wall of oropharynx	4	0
C10.8	Overlapping lesion of oropharynx	1	0
C10.9	Oropharynx, NOS	48	1
C11.1	Posterior wall of nasopharynx	0	3
C11.9	Nasopharynx, NOS	37	17
C12.9	Pyriform sinus	214	30
C13.0	Postcricoid region	41	28
C13.1	Aryepiglottic fold	55	2
C13.2	Posterior wall of hypopharynx	11	0
C13.8	Overlapping lesion of hypopharynx	4	0
C13.9	Laryngopharynx, Hypopharynx NOS	34	3
C14.0	Pharynx, NOS	97	26
C14.8	Overlapping lesion of lip, oral cavity, pharynx	4	0
Total		854	156

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	45	13
8004	Malignant tumour, spindle cell type	1	1
8010	Carcinoma, NOS	22	3
8070	Squamous cell carcinoma, NOS	719	125
8071	Squamous cell carcinoma, keratinizing, NOS	27	2
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	13	6
8076	Squamous cell carcinoma, microinvasive	16	2
8083	Basaloid squamous cell carcinoma	2	0
8140	Adenocarcinoma, NOS	4	0
8200	Adenoid cystic carcinoma	0	1
8260	Papillary adenocarcinoma, NOS	1	0
8430	Mucoepidermoid carcinoma	1	1
8480	Mucinous adenocarcinoma	0	1
8560	Adenosquamous carcinoma	1	0
8801	Spindle cell sarcoma	1	0
8813	Fascial fibrosarcoma	0	1
8920	Alveolar rhabdomyosarcoma	1	0
Total		854	156




Figure 22: Age specific rates of Pharyngeal cancer in Sri Lanka in 2017




Figure 23: Age standardized incidence rates of Pharyngeal cancer in Sri Lanka, 2012 - 2017

Table 12: Oesophageal cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	1167	7.5	10.4	1.40
Female	843	5.0	6.1	0.81

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C15.0	Cervical oesophagus	1	2
C15.1	Thoracic oesophagus	6	7
C15.2	Abdominal oesophagus	6	6
C15.3	Upper third of oesophagus	40	28
C15.4	Middle third of oesophagus	137	123
C15.5	Lower third of oesophagus	186	119
C15.8	Overlapping lesion of oesophagus	5	4
C15.9	Oesophagus, NOS	786	554
Total		1167	843

ICD O Code & histology		Male	Female
8000	Neoplasm, malignant	96	59
8010	Carcinoma, NOS	29	23
8041	Small cell carcinoma, NOS	2	0
8070	Squamous cell carcinoma, NOS	813	661
8071	Squamous cell carcinoma, keratinizing, NOS	11	12
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	2	1
8076	Squamous cell carcinoma, microinvasive	20	17
8083	Basaloid squamous cell carcinoma	1	1
8140	Adenocarcinoma, NOS	176	60
8240	Carcinoid tumour, NOS	1	0
8246	Neuroendocrine carcinoma, NOS	2	0
8260	Papillary adenocarcinoma, NOS	0	1
8480	Mucinous adenocarcinoma	3	1
8490	Signet ring cell carcinoma	9	1
8560	Adenosquamous carcinoma	1	2
8720	Malignant melanoma, NOS (except juvenile melanoma M-8770/0)	0	1
8890	Leimyosarcoma, NOS	0	1
8936	Gastrointestinal stromal sarcoma	1	2
Total		1167	843




Figure 24: Age specific incidence rates of Oesophageal cancer in Sri Lanka in 2017




Figure 25: Age standardized incidence rates of Oesophageal cancer in Sri Lanka, 2005 - 2017

Table 13: Stomach cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	525	3.4	4.7	0.61
Female	219	1.3	1.7	0.22

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C16.0	Cardia, NOS	172	76
C16.1	Fundus of stomach	10	2
C16.2	Body of stomach	8	2
C16.3	Gastric antrum	15	3
C16.4	Pylorus	45	21
C16.5	Lesser curvature of stomach	8	1
C16.6	Greater curvature of stomach	4	1
C16.8	Overlapping lesion of stomach	2	2
C16.9	Stomach, NOS	261	111
Total		525	219

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	65	24
8004	Malignant tumor, spindle cell type	1	0
8010	Carcinoma, NOS	30	13
8032	Spindle cell carcinoma, NOS	1	1
8070	Squamous cell carcinoma, NOS	38	38
8071	Squamous cell carcinoma, keratinizing, NOS	0	2
8076	Squamous cell carcinoma, microinvasive	1	0
8140	Adenocarcinoma, NOS	307	107
8144	Adenocarcinoma, intestinal type	20	5
8145	Carcinoma, diffuse type	3	1
8211	Tubular adenocarcinoma	2	0
8246	Neuroendocrine carcinoma, NOS	1	5
8323	Mixed cell adenocarcinoma	0	1
8480	Mucinous adenocarcinoma	10	1
8490	Signet ring cell carcinoma	33	7
8801	Spindle cell sarcoma	1	1
8936	Gastrointestinal stromal sarcoma	12	13
Total		525	219




Figure 26: Age specific incidence rates of Stomach cancer in Sri Lanka in 2017




Figure 27: Age standardized incidence rates of Stomach cancer in Sri Lanka, 2005 - 2017

Table 14: Colon and rectal cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	1289	8.3	11.7	1.49
Female	1333	8.0	9.9	1.24

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code & site		Male	Female
C18.0	Cecum	40	50
C18.1	Appendix	10	25
C18.2	Ascending colon	34	36
C18.3	Hepatic flexure of colon	5	9
C18.4	Transverse colon	21	31
C18.5	Splenic flexure of colon	5	4
C18.6	Descending colon	23	19
C18.7	Sigmoid colon	208	195
C18.8	Overlapping lesion of colon	1	4
C18.9	Colon, NOS	223	275
C19.9	Rectosigmoid junction	95	87
C20.9	Rectum, NOS	624	598
Total		1289	1333

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	127	120
8001	Tumour cells, malignant	0	1
8010	Carcinoma, NOS	19	28
8032	Spindle cell carcinoma, NOS	1	2
8070	Squamous cell carcinoma, NOS	18	29
8071	Squamous cell carcinoma, keratinizing, NOS	0	1
8076	Squamous cell carcinoma, microinvasive	0	1
8083	Basaloid squamous cell carcinoma	1	0
8120	Transitional cell carcinoma, NOS	0	1
8140	Adenocarcinoma, NOS	1024	1062
8141	Scirrhous adenocarcinoma	1	0
8211	Tubular adenocarcinoma	4	3
8240	Carcinoid tumor, NOS	3	4
8243	Goblet cell carcinoid	0	1
8246	Neuroendocrine carcinoma, NOS	13	10
8260	Papillary adenocarcinoma, NOS	0	2
8262	Villous adenocarcinoma	2	1
8263	Adenocarcinoma in tubulovillous adenoma	4	2
8310	Clear cell adenocarcinoma, NOS	0	1
8480	Mucinous adenocarcinoma	57	44
8490	Signet ring cell carcinoma	8	15
8550	Acinar cell carcinoma	0	1
8560	Adenosquamous carcinoma	0	2
8720	Malignant melanoma, NOS (except juvenile melanoma M-8770/0)	1	0

Table 14 continued ...

ICD O code and histology		Male	Female
8772	Spindle cell melanoma, NOS	0	1
8800	Sarcoma, NOS	1	0
8854	Pleomorphic liposarcoma	0	1
8890	Leimyosarcoma, NOS	1	0
8936	Gastrointestinal stromal sarcoma	4	0
Total		1289	1333




Figure 28: Age specific incidence rates of Colon and Rectal cancer in Sri Lanka in 2017




Figure 29: Age standardized incidence rates of Colon and Rectal cancer in Sri Lanka, 2005 – 2017

Table 15: Laryngeal cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	737	4.8	6.6	0.87
Female	73	0.4	0.5	0.06

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C32.0	Glottis	384	29
C32.1	Supraglottis	237	28
C32.2	Subglottis	9	1
C32.3	Laryngeal cartilage	7	0
C32.8	Overlapping lesion of larynx	1	0
C32.9	Larynx, NOS	99	15
Total		737	73

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	49	11
8010	Carcinoma, NOS	7	1
8032	Spindle cell carcinoma, NOS	1	0
8051	Verrucous carcinoma, NOS	2	0
8070	Squamous cell carcinoma, NOS	629	57
8071	Squamous cell carcinoma, keratinizing, NOS	25	2
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	4	0
8075	Squamous cell carcinoma, adenoid	2	0
8076	Squamous cell carcinoma, microinvasive	8	1
8083	Basaloid squamous cell carcinoma	6	0
8140	Adenocarcinoma, NOS	1	0
8200	Adenoid cystic carcinoma	3	1
Total		737	73




Figure 30: Age specific incidence rates of Laryngeal cancer in Sri Lanka in 2017




Figure 31: Age standardized incidence rates of Laryngeal cancer in Sri Lanka, 2005 - 2017

Table 16: Trachea, Bronchus and Lung cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	1338	8.7	12.1	1.65
Female	468	2.8	3.6	0.47

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C33.9	Trachea	19	3
C34.0	Main bronchus	32	7
C34.1	Upper lobe, lung	118	23
C34.2	Middle lobe, lung	13	5
C34.3	Lower lobe, lung	54	28
C34.8	Overlapping lesion of lung	11	4
C34.9	Lung, NOS	1091	398
Total		1338	468

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	245	77
8001	Tumour cells, malignant	1	1
8002	Malignant tumour, small cell type	1	0
8004	Malignant tumor, spindle cell type	1	0
8010	Carcinoma, NOS	78	31
8012	Large cell carcinoma, NOS	3	2
8032	Spindle cell carcinoma, NOS	1	0
8041	Small cell carcinoma, NOS	87	20
8042	Oat cell carcinoma	1	0
8046	Non-small cell carcinoma	250	76
8070	Squamous cell carcinoma, NOS	275	29
8071	Squamous cell carcinoma, keratinizing, NOS	2	0
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	9	0
8073	Squamous cell carcinoma, small cell, nonkeratinizing	1	1
8076	Squamous cell carcinoma, microinvasive	4	1
8083	Basaloid squamous cell carcinoma	1	0
8140	Adenocarcinoma, NOS	320	181
8200	Adenoid cystic carcinoma	3	3
8211	Tubular adenocarcinoma	1	0
8240	Carcinoid tumor, NOS	10	14
8246	Neuroendocrine carcinoma, NOS	3	1
8249	Atypical carcinoid tumour	0	2
8250	Bronchiolo-alveolar adenocarcinoma, NOS	2	3
8260	Papillary adenocarcinoma, NOS	3	0
8310	Clear cell adenocarcinoma, NOS	1	2
8430	Mucoepidermoid carcinoma	1	3
8480	Mucinous adenocarcinoma	8	6
8481	Mucin-producing adenocarcinoma	1	0
8490	Signet ring cell carcinoma	1	1

Table 16 continued ...

ICD O code and histology	Male	Female
8550 Acinar cell carcinoma	8	6
8560 Adenosquamous carcinoma	1	2
8800 Sarcoma, NOS	2	2
8803 Small cell sarcoma	4	0
8806 Desmoplastic small round cell tumour	6	4
8840 Myxosarcoma	1	0
8852 Myxoid liposarcoma	1	0
8890 Leiomyosarcoma, NOS	1	0
Total	1338	468




Figure 32: Age specific incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka in 2017




Figure 33: Age standardized incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka, 2005 – 2017

Table 17: Skin cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	462	3.0	4.1	0.50
Female	328	2.0	2.4	0.30

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C43.0	Malignant melanoma of lip	0	1
C43.1	Malignant melanoma of eyelid, including canthus	1	1
C43.3	Malignant melanoma of other and unspecified parts of face	1	1
C43.5	Malignant melanoma of trunk	2	3
C43.6	Malignant melanoma of upper limb, including shoulder	3	0
C43.7	Malignant melanoma of lower limb, including hip	27	25
C43.9	Malignant melanoma of skin, unspecified	11	7
C44.0	Skin of lip, NOS	6	1
C44.1	Eyelid	14	24
C44.2	External ear	15	19
C44.3	Skin of other & unspecified parts of face	70	69
C44.4	Skin of scalp and neck	52	29
C44.5	Skin of trunk	50	27
C44.6	Skin of upper limb and shoulder	23	19
C44.7	Skin of lower limb and hip	124	64
C44.9	Skin, NOS	63	38
Total		462	328

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	24	14
8004	Malignant tumor, spindle cell type	4	1
8010	Carcinoma, NOS	7	5
8022	Pleomorphic carcinoma	2	0
8031	Giant cell carcinoma	1	0
8032	Spindle cell carcinoma, NOS	3	4
8035	Carcinoma with osteoclast-like giant cells	1	0
8051	Verrucous carcinoma, NOS	13	1
8070	Squamous cell carcinoma, NOS	253	135
8071	Squamous cell carcinoma, keratinizing, NOS	8	3
8075	Squamous cell carcinoma, adenoid	1	0
8076	Squamous cell carcinoma, microinvasive	2	1
8083	Basaloid squamous cell carcinoma	0	1
8090	Basal cell carcinoma, NOS	60	86
8091	Multifocal superficial basal cell carcinoma	0	3
8094	Basosquamous carcinoma	2	3
8097	Basal cell carcinoma, nodular	4	2
8140	Adenocarcinoma, NOS	9	6
8200	Adenoid cystic carcinoma	3	4
8247	Merkel cell carcinoma	1	0

Table 17 continued ...

ICD O code and histology	Male	Female
8390 Skin appendage carcinoma	1	1
8401 Apocrine adenocarcinoma	1	0
8409 Eccrine poroma, malignant	2	2
8410 Sebaceous adenocarcinoma	1	9
8480 Mucinous adenocarcinoma	3	0
8542 Paget disease, extramammary	1	0
8550 Acinar cell carcinoma	0	1
8720 Malignant melanoma, NOS (except juvenile melanoma M-8770/0)	43	31
8721 Nodular melanoma	0	1
8730 Amelanotic melanoma	1	1
8744 Acral lentiginous melanoma, malignant	1	4
8771 Epithelioid cell melanoma	0	1
8832 Dermatofibrosarcoma, NOS	10	8
Total	462	328




Figure 34: Age specific incidence rates of Skin cancer in Sri Lanka in 2017




Figure 35: Age standardized incidence rates of Skin cancer in Sri Lanka, 2005 - 2017

Table 18: Breast cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	143	0.9	1.3	0.16
Female	4193	25.1	32.1	3.74

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C50.0	Nipple	1	11
C50.1	Central portion of breast	1	50
C50.2	Upper-inner quadrant of breast	0	37
C50.3	Lower-inner quadrant of breast	0	22
C50.4	Upper-outer quadrant of breast	2	126
C50.5	Lower-outer quadrant of breast	0	36
C50.6	Axillary tail of breast	0	2
C50.8	Overlapping lesion of breast	0	56
C50.9	Breast, NOS	139	3853
Total		143	4193

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	16	426
8001	Tumor cells, malignant	0	1
8002	Malignant tumour, small cell type	1	0
8004	Malignant tumor, spindle cell type	0	3
8010	Carcinoma, NOS	13	692
8032	Spindle cell carcinoma, NOS	0	1
8050	Papillary carcinoma, NOS	0	21
8070	Squamous cell carcinoma, NOS	6	20
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	2
8120	Transitional cell carcinoma, NOS	1	1
8140	Adenocarcinoma, NOS	1	43
8201	Cribiform carcinoma, NOS	0	4
8211	Tubular adenocarcinoma	0	5
8246	Neuroendocrine carcinoma, NOS	0	3
8260	Papillary adenocarcinoma, NOS	0	13
8320	Granular cell carcinoma	0	1
8480	Mucinous adenocarcinoma	3	73
8481	Mucin-producing adenocarcinoma	0	1
8490	Signet ring cell carcinoma	1	0
8500	Infiltrating duct carcinoma, NOS	98	2533
8501	Comedocarcinoma, NOS	0	1
8502	Secretory carcinoma of breast	0	2
8503	Intraductal papillary adenocarcinoma with invasion	2	11
8504	Intracystic carcinoma, NOS	0	3
8510	Medullary carcinoma, NOS	0	22
8513	Atypical medullary carcinoma	0	1
8520	Lobular carcinoma, NOS	0	111

Table 18 continued ...

ICD O code and histology	Male	Female
8521 Infiltrating ductular carcinoma	0	35
8522 Infiltrating duct and lobular carcinoma	0	20
8523 Infiltrating duct mixed with other types of carcinoma	0	1
8530 Inflammatory carcinoma	0	2
8540 Paget disease, mammary	1	5
8541 Paget disease and infiltrating duct carcinoma of breast	0	1
8543 Paget disease and intraductal carcinoma of breast	0	3
8573 Adenocarcinoma with apocrine metaplasia	0	1
8575 Metaplastic carcinoma, NOS	0	11
8800 Sarcoma, NOS	0	1
8802 Giant cell sarcoma	0	1
8810 Fibrosarcoma, NOS	0	2
8900 Rhabdomyosarcoma, NOS	0	1
9020 Phyllodes tumor, malignant	0	12
9120 Hemangiosarcoma	0	1
9580 Granular cell tumour, malignant	0	1
Total	143	4193




Figure 36: Age specific incidence rates of Breast cancer in Sri Lanka in 2017




Figure 37: Age standardized incidence rates of Breast cancer in Sri Lanka, 2005 - 2017

Table 19: Cervix uteri cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Female	1071	6.4	8.1	1.00

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and side	No.
C53.0 Endocervix	60
C53.1 Exocervix	23
C53.8 Overlapping lesion of cervix	9
C53.9 Cervix uteri	979
Total	1071

ICD O Code and histology	No.
8000 Neoplasm, malignant	90
8010 Carcinoma, NOS	17
8032 Spindle cell carcinoma, NOS	1
8041 Small cell carcinoma, NOS	1
8052 Papillary squamous cell carcinoma	2
8070 Squamous cell carcinoma, NOS	643
8071 Squamous cell carcinoma, keratinizing, NOS	88
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	129
8076 Squamous cell carcinoma, microinvasive	11
8083 Basaloid squamous cell carcinoma	4
8140 Adenocarcinoma, NOS	57
8246 Neuroendocrine carcinoma, NOS	3
8260 Papillary adenocarcinoma, NOS	1
8310 Clear cell adenocarcinoma, NOS	2
8380 Endometrioid adenocarcinoma, NOS	8
8480 Mucinous adenocarcinoma	10
8560 Adenosquamous carcinoma	1
8720 Malignant melanoma, NOS (except juvenile melanoma M-8770/0)	1
8890 Leiomyosarcoma, NOS	1
8980 Carcinosarcoma, NOS	1
Total	1071




Figure 38: Age specific incidence rates of Cervical cancer in Sri Lanka in 2017




Figure 39: Age standardized incidence rates of Cervical cancer in Sri Lanka, 2005 - 2017

Table 20: Uterine cancer incidence data in Sri Lanka, 2017

Group		Number	%	ASR	Cum. Rate
Female		1008	6.0	7.6	1.00

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD O code and site		No.
C54.0	Isthmus uteri	1
C54.1	Endometrium	663
C54.2	Myometrium	1
C54.3	Fundus uteri	3
C54.8	Overlapping lesion of corpus	1
C54.9	Corpus uteri	14
C55.9	Uterus, NOS	325
Total		1008

ICD O code and histology		No.
8000	Neoplasm, malignant	67
8004	Malignant tumor, spindle cell type	1
8010	Carcinoma, NOS	16
8022	Pleomorphic carcinoma	1
8032	Spindle cell carcinoma, NOS	2
8041	Small cell carcinoma, NOS	1
8050	Papillary carcinoma, NOS	6
8052	Papillary Squamous cell carcinoma	1
8070	Squamous cell carcinoma, NOS	41
8071	Squamous cell carcinoma, keratinizing, NOS	5
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	12
8076	Squamous cell carcinoma, microinvasive	1
8140	Adenocarcinoma, NOS	241
8260	Papillary adenocarcinoma, NOS	9
8262	Villous adenocarcinoma	1
8310	Clear cell adenocarcinoma, NOS	9
8380	Endometrioid adenocarcinoma, NOS	509
8440	Cystadenocarcinoma, NOS	4
8480	Mucinous adenocarcinoma	3
8562	Epithelial-myoepithelial carcinoma	1
8800	Sarcoma, NOS	6
8801	Spindle cell sarcoma	1
8890	Leiomyosarcoma, NOS	14
8896	Myxoid leiomyosarcoma	2
8930	Endometrial stromal sarcoma, NOS	10
8931	Endometrial stromal sarcoma, low grade	2
8933	Adenosarcoma	1
8935	Stromal sarcoma, NOS	9
8950	Mullerian mixed tumor	9

Table 20 continued ...

ICD O code and histology		No.
8980	Carcinosarcoma, NOS	20
9100	Choriocarcinoma, NOS	3
Total		1008




Figure 40: Age specific incidence rates of Uterine cancer in Sri Lanka in 2017




Figure 41: Age standardized incidence rates of Uterine cancer in Sri Lanka, 2005 - 2017

Table 21: Ovarian cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Female	1065	6.4	8.3	0.96

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	No.
C56.9 Ovary	1065
Total	1065

ICD O code and histology	No.
8000 Neoplasm, malignant	136
8001 Tumour cells, malignant	1
8004 Malignant tumour, spindle cell type	3
8010 Carcinoma, NOS	17
8032 Spindle cell carcinoma, NOS	1
8050 Papillary carcinoma, NOS	2
8070 Squamous cell carcinoma, NOS	14
8140 Adenocarcinoma, NOS	128
8240 Carcinoid tumour, NOS	2
8246 Neuroendocrine carcinoma, NOS	1
8260 Papillary adenocarcinoma, NOS	27
8310 Clear cell adenocarcinoma, NOS	26
8320 Granular cell carcinoma	5
8380 Endometrioid adenocarcinoma, NOS	51
8382 Endometrioid adenocarcinoma, secretory variant	1
8440 Cystadenocarcinoma, NOS	3
8441 Serous cystadenocarcinoma, NOS	192
8450 Papillary cystadenocarcinoma, NOS	6
8460 Papillary serous cystadenocarcinoma	224
8461 Serous surface papillary carcinoma	18
8470 Mucinous cystadenocarcinoma, NOS	33
8471 Papillary mucinous cystadenocarcinoma	6
8480 Mucinous adenocarcinoma	38
8481 Mucin-producing adenocarcinoma	1
8500 Infiltrating duct carcinoma, NOS	1
8550 Acinar cell carcinoma	1
8620 Granulosa cell tumor, malignant	36
8631 Sertoli-Leydig cell tumor, poorly differentiated	2
8810 Fibrosarcoma, NOS	2
8890 Leiomyosarcoma, NOS	2
8933 Adenosarcoma	1
8935 Stromal sarcoma, NOS	2
8980 Carcinosarcoma, NOS	4
9000 Brenner tumor, malignant	4
9014 Serous adenocarcinofibroma	5

Table 21 continued ...

ICD O code and histology		No.
9060	Dysgerminoma	25
9064	Germinoma	9
9070	Embryonal carcinoma, NOS	2
9071	Yolk sac tumor	11
9080	Teratoma, malignant, NOS	9
9085	Mixed germ cell tumor	10
9100	Choriocarcinoma, NOS	1
9580	Granular cell tumor, malignant	2
Total		1065




Figure 42: Age specific incidence rates of Ovarian cancer in Sri Lanka in 2017




Figure 43: Age standardized incidence rates of Ovarian cancer in Sri Lanka, 2005 - 2017

Table 22: Prostate cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	1070	6.9	9.9	1.29

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and histology		No.
C61.9	Prostate gland	1070
Total		1070

ICD O code and histology		No.
8000	Neoplasm, malignant	180
8010	Carcinoma, NOS	15
8033	Pseudosarcomatous carcinoma	1
8070	Squamous cell carcinoma, NOS	5
8120	Transitional cell carcinoma, NOS	4
8140	Adenocarcinoma, NOS	610
8246	Neuroendocrine carcinoma, NOS	1
8500	Infiltrating duct carcinoma, NOS	2
8550	Acinar cell carcinoma	247
8551	Acinar cell cystadenocarcinoma	4
8815	Solitary fibrous tumour, malignant	1
Total		1070




Figure 44: Age specific incidence rates of Prostate cancer in Sri Lanka in 2017




Figure 45: Age standardized incidence rates of Prostate cancer in Sri Lanka, 2005 - 2017

Table 23: Urinary Bladder cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	678	4.4	6.2	0.79
Female	171	1.0	1.3	0.16

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C67.2	Lateral wall of bladder	1	1
C67.3	Anterior wall of bladder	2	0
C67.4	Posterior wall of bladder	2	1
C67.7	Urachus	3	0
C67.8	Overlapping lesion of bladder	4	1
C67.9	Urinary bladder, NOS	666	168
Total		678	171

ICD O code and histology		Male	Female
8000	Neoplasm, malignant	69	21
8010	Carcinoma, NOS	19	3
8033	Pseudosarcomatous carcinoma	1	0
8050	Papillary carcinoma, NOS	9	2
8070	Squamous cell carcinoma, NOS	10	4
8071	Squamous cell carcinoma, keratinizing, NOS	1	0
8120	Transitional cell carcinoma, NOS	293	61
8122	Transitional cell carcinoma, spindle cell	1	0
8130	Papillary transitional cell carcinoma	254	67
8131	Transitional cell carcinoma, micropapillary	2	0
8140	Adenocarcinoma, NOS	13	9
8246	Neuroendocrine carcinoma, NOS	1	0
8260	Papillary adenocarcinoma, NOS	1	0
8480	Mucinous adenocarcinoma	3	1
8490	Signet ring cell carcinoma	0	1
8550	Acinar cell carcinoma	0	1
8900	Rhabdomyosarcoma, NOS	1	0
8910	Embryonal Rhabdomyosarcoma, NOS	0	1
Total		678	171




Figure 46: Age specific incidence rates of Urinary Bladder cancer in Sri Lanka in 2017




Figure 47: Age standardized incidence rates of Urinary Bladder cancer in Sri Lanka, 2005 - 2017

Table 24: Thyroid gland cancer incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	473	3.1	4.1	0.42
Female	2014	12.1	16.1	1.49

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C73.9 Thyroid gland		473	2014
Total		473	2014

ICD 0 code and histology		Male	Female
8000 Neoplasm, malignant		26	50
8001 Tumour cells, malignant		0	1
8010 Carcinoma, NOS		8	12
8021 Carcinoma, anaplastic, NOS		7	18
8050 Papillary carcinoma, NOS		19	99
8070 Squamous cell carcinoma, NOS		2	6
8140 Adenocarcinoma, NOS		1	3
8143 Superficial spreading adenocarcinoma		0	1
8260 Papillary adenocarcinoma, NOS		259	934
8290 Oxyphilic adenocarcinoma		7	38
8330 Follicular adenocarcinoma, NOS		47	271
8331 Follicular adenocarcinoma, well differentiated		1	3
8335 Follicular carcinoma, minimally invasive		11	74
8340 Papillary carcinoma, follicular variant		31	225
8341 Papillary microcarcinoma		42	254
8342 Papillary carcinoma, oxyphilic cell		0	1
8343 Papillary carcinoma, encapsulated		1	4
8346 Mixed medullary-follicular carcinoma		0	2
8347 Mixed medullary-papillary carcinoma		1	0
8430 Mucoepidermoid carcinoma		0	1
8510 Medullary carcinoma, NOS		10	17
Total		473	2014




Figure 48: Age specific incidence rates of Thyroid gland cancer in Sri Lanka in 2017




Figure 49: Age standardized incidence rates of Thyroid gland cancer in Sri Lanka, 2005 - 2017

Table 25: Lymphoma incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	665	4.3	6.1	0.71
Female	465	2.8	3.7	0.39

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female
C81.0 Nodular lymphocyte predominant Hodgkin lymphoma	3	1
C81.1 Nodular sclerosis (classical) Hodgkin lymphoma	21	25
C81.2 Mixed cellularity (classical) Hodgkin lymphoma	13	14
C81.3 Lymphocyte depleted (classical) Hodgkin lymphoma	1	0
C81.4 Lymphocyte-rich(classical) Hodgkin lymphoma	4	1
C81.9 Hodgkin lymphoma, unspecified	94	63
C82.0 Follicular lymphoma grade I	2	2
C82.1 Follicular lymphoma grade II	1	1
C82.2 Follicular lymphoma grade III, unspecified	0	1
C82.9 Follicular lymphoma, NOS	47	29
C83.0 Small cell B-cell lymphoma	2	5
C83.1 Mantle cell lymphoma	1	1
C83.3 Diffuse large B-cell lymphoma	55	44
C83.5 Lymphoblastic (diffuse) lymphoma	10	3
C83.7 Burkitt lymphoma, NOS	5	2
C83.8 Other non-follicular lymphoma	0	1
C84.0 Mycosis fungoides	7	4
C84.4 Peripheral T-cell lymphoma, not elsewhere classified	11	5
C84.6 Anaplastic large cell lymphoma, ALK-positive	5	3
C84.8 Cutaneous T-cell lymphoma, unspecified	2	1
C85.7 Other specified types of non-Hodgkin lymphoma	17	9
C85.9 Non-Hodgkin lymphoma, unspecified	358	245
C96.4 Sarcoma of dendritic cells (accessory cells)	0	2
C96.6 Unifocal Langerhans-cell histiocytosis	4	3
C96.8 Histiocytic sarcoma	2	0
Total	665	465

ICD O code & histology	Male	Female
9590 Malignant lymphoma, NOS	74	50
9591 Malignant lymphoma, non-Hodgkin, NOS	281	193
9596 Composite Hodgkin and non-Hodgkin lymphoma	17	9
9650 Hodgkin lymphoma, NOS	94	63
9651 Hodgkin lymphoma, lymphocyte-rich	4	1
9652 Hodgkin lymphoma, mixed cellularity, NOS	13	14
9653 Hodgkin lymphoma, lymphocyte depletion, NOS	1	0
9659 Hodgkin lymphoma, nodular lymphocyte predominance	3	1
9663 Hodgkin lymphoma, nodular sclerosis, NOS	18	24
9664 Hodgkin lymphoma, nodular sclerosis, cellular phase	1	0
9665 Hodgkin lymphoma, nodular sclerosis, grade 1	2	0

Table 25 continued ...

ICD O code & histology	Male	Female
9667 Hodgkin lymphoma, nodular sclerosis, grade 2	0	1
9670 Malignant lymphoma, small B lymphocytic, NOS	1	2
9671 Malignant lymphoma, lymphoplasmacytic	1	1
9673 Mantle cell lymphoma (includes all variants: blastic, pleomorphic, small cell)	1	1
9678 Primary effusion lymphoma	0	1
9680 Malignant lymphoma, large B-cell, diffuse, NOS	55	44
9687 Burkitt lymphoma, NOS	5	2
9689 Splenic marginal zone B-cell lymphoma	0	2
9690 Follicular lymphoma, NOS	47	29
9691 Follicular lymphoma, grade 2	1	1
9695 Follicular lymphoma, grade 1	2	2
9698 Follicular lymphoma, grade 3	0	1
9700 Mycosis fungoides	7	4
9702 Mature T-cell lymphoma, NOS	11	5
9705 Angioimmunoblastic T-cell lymphoma	1	1
9708 Subcutaneous panniculitis-like T-cell lymphoma	0	1
9709 Cutaneous T-cell lymphoma, NOS	2	1
9714 Anaplastic large cell lymphoma, T cell and Null cell type	5	3
9718 Primary cutaneous CD30+ T-cell lymphoproliferative disorder	1	0
9719 NK/T-cell lymphoma, nasal and nasal-type	1	0
9727 Precursor cell lymphoblastic lymphoma, NOS	6	1
9729 Precursor T-cell lymphoblastic lymphoma	4	2
9750 Malignant histiocytosis	1	0
9751 Langerhans cell histiocytosis, NOS	4	3
9755 Histiocytic sarcoma	1	0
9758 Follicular dendritic cell sarcoma	0	2
Total	665	465




Figure 50: Age specific incidence rates of Lymphoma in Sri Lanka in 2017




Figure 51: Age standardized incidence rates of Lymphoma in Sri Lanka, 2011 - 2017

Table 26: Leukaemia incidence data in Sri Lanka, 2017

Group	Number	%	ASR	Cum. Rate
Male	442	2.9	4.3	0.37
Female	372	2.2	3.2	0.30

ASR – Age Standardized Incidence Rate per 100,000 world population

Cum. Rate – Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male	Female
C91.0	Acute lymphoblastic leukaemia (ALL)	152	100
C91.1	Chronic lymphocytic leukaemia of B-cell type	37	20
C91.3	Prolymphocytic leukemia of B-cell type	2	0
C91.4	Hairy-cell leukemia	3	3
C91.8	Mature B-cell leukaemia Burkitt-type	2	1
C91.9	Lymphoid leukaemia, unspecified	10	4
C92.0	Acute myeloblastic leukaemia (AML)	127	143
C92.1	Chronic myeloid leukemia (CML), BCR/ABL-positive	65	56
C92.3	Myeloid sarcoma	1	1
C92.4	Acute promyelocytic leukemia	8	11
C92.5	Acute myelomonocytic leukemia	7	7
C92.8	Acute myeloid leukemia with multilineage dysplasia	0	1
C92.9	Myeloid leukemia, unspecified	3	1
C93.0	Acute monoblastic/monocytic leukemia	7	7
C93.1	Chronic myelomonocytic leukemia	1	1
C93.3	Juvenile myelomonocytic leukemia	0	1
C94.0	Acute erythroid leukemia	3	1
C94.2	Acute megakaryoblastic leukemia	0	2
C94.4	Acute panmyelosis with myelofibrosis	3	2
C95.0	Acute leukemia of unspecified cell type	6	8
C95.9	Leukemia, unspecified	5	2
Total		442	372

ICD O code and histology		Male	Female
9800	Leukemia, NOS	5	2
9801	Acute leukemia, NOS	6	8
9820	Lymphoid leukemia, NOS	10	4
9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	37	20
9826	Burkitt cell leukemia	2	1
9832	Prolymphocytic leukemia, NOS	2	0
9835	Precursor cell lymphoblastic leukemia, NOS	140	90
9836	Precursor B-cell lymphoblastic leukemia	5	8
9837	Precursor T-cell lymphoblastic leukemia	7	2
9840	Acute myeloid leukemia, M6 type	3	1
9860	Myeloid leukemia, NOS	3	1
9861	Acute myeloid leukemia, NOS	95	111
9863	Chronic myeloid leukemia, NOS	63	55
9866	Acute promyelocytic leukemia	8	11
9867	Acute myelomonocytic leukemia	7	7

Table 26 continued ...

ICD O code and histology		Male	Female
9872	Acute myeloid leukemia, minimal differentiation	2	1
9873	Acute myeloid leukemia without maturation	2	4
9874	Acute myeloid leukemia with maturation	28	27
9875	Chronic myelogenous leukemia, BCR/ABL positive	2	1
9891	Acute monocytic leukemia	7	7
9895	Acute myeloid leukemia with myelodysplasia-related changes	0	1
9910	Acute megakaryoblastic leukemia	0	2
9930	Myeloid sarcoma	1	1
9931	Acute panmyelosis with myelofibrosis	3	2
9940	Hairy cell leukemia	3	3
9945	Chronic myelomonocytic leukemia, NOS	1	1
9946	Juvenile myelomonocytic leukemia	0	1
Total		442	372




Figure 52: Age specific incidence rates of Leukaemia in Sri Lanka in 2017




Figure 53: Age standardized incidence rates of Leukaemia in Sri Lanka, 2011 - 2017

Clinical staging at the point of diagnosis of Breast, Cervix and Lip, Tongue and Mouth cancers in Sri Lanka, 2017

Figure 54, 55 and 56 give the clinical staging information at the point of diagnosis of Breast, Cervix and Lip, Tongue and Mouth cancers. Information on clinical staging was available for 13% of diagnosed Breast cancers, 30% of diagnosed Cervical cancers and 8% of diagnosed Lip, Tongue and Mouth cancers. The percentages computed are out of the cancers with staging information.



Figure 54: Clinical stage at diagnosis of Breast cancers in Sri Lanka, 2017




Figure 55: Clinical stage at diagnosis of Cervical cancers in Sri Lanka, 2017





Figure 56: Clinical stage at diagnosis of Lip, Tongue and Mouth cancers in Sri Lanka, 2017


Table 27: Basis of diagnosis of cancer patients in Sri Lanka, 2017

Basis of diagnosis	Frequency	Percentage
Diagnosed microscopically		
Histology of primary	28287	87.9
Histology of metastasis	1112	3.5
Cytology/Haematology only	529	1.6
Subtotal	29928	93
Diagnosed non-microscopically		
Clinical investigation including X-ray, USS, CT, etc. (imaging only)	457	1.4
Death certificate only	1370	4.3
Clinical only	31	0.1
Specific biochemical/immunological test only	5	0
Exploratory surgery	49	0.2
Subtotal	1912	5.9
Unknown/Not recorded	330	1
Total	32170	100


**Figure 57: Basis of diagnosis of cancers in Sri Lanka, 2017**




Percentage of patients who received surgical treatment



Percentage of patients who received radiotherapy treatment



Percentage of patients who received chemotherapy treatment



Percentage of patients who received hormone therapy

Figure 58: Percentage of newly detected cancer patients who received different types of treatment in Sri Lanka, 2017

Table 28: Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2017 according to International Classification of Childhood Cancer third edition (ICCC-3) by sex

ICCC-3 Site Group	ICD -O-3 Histology		Male	Female	Total
I Leukaemias, myeloproliferative diseases, and myelodyspastic diseases					
a. Lymphoid leukaemia	9820	Lymphoid leukaemia, NOS	2	1	3
	9823	B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma	1	0	1
	9826	Burkitt cell leukaemia	2	0	2
	9835	Precursor cell lymphoblastic leukaemia, NOS	99	63	162
	9836	Precursor B-cell lymphoblastic leukaemia	1	0	1
	9837	Precursor T-cell lymphoblastic leukaemia	2	1	3
b. Acute myeloid leukaemia	9840	Acute myeloid leukaemia, M6 type	1	0	1
	9861	Acute myeloid leukaemia, NOS	13	11	24
	9866	Acute promyelocytic leukaemia, t(15;17) (q22;q11-12)	2	0	2
	9867	Acute myelomonocytic leukaemia	1	0	1
	9874	Acute myeloid leukaemia with maturation	3	2	5
	9891	Acute monocytic leukaemia	1	0	1
	9910	Acute megakaryoblastic leukaemia	0	2	2
c. Chronic myeloproliferative diseases	9863	Chronic myeloid leukaemia, NOS	1	1	2
d. Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukaemia	0	1	1
	9989	Myelodysplastic syndrome, NOS	2	0	2
e. Unspecified and other specified leukaemia	9800	Leukaemia, NOS	2	0	2
	9801	Acute leukaemia, NOS	0	1	1
Total			133	83	216

Table 28 continued ...

ICCC-3 Site Group	ICD -O-3 Histology		Male	Female	Total
II Lymphomas and reticuloendothelial neoplasms					
a. Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	9	11	20
	9651	Hodgkin lymphoma, lymphocyte-rich	1	0	1
	9652	Hodgkin lymphoma, mixed cellularity, NOS	5	3	8
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	1	0	1
	9663	Hodgkin lymphoma, nodular sclerosis, NOS	2	6	8
	9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	1	0	1
b. Non-Hodgkin lymphomas (except Burkitt lymphoma)	9591	Malignant lymphoma, non-Hodgkin, NOS	10	3	13
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	1	1	2
	9690	Follicular lymphoma, NOS	0	1	1
	9699	Marginal zone B-cell lymphoma, NOS	1	0	1
	9700	Mycosis fungoides	2	0	2
	9702	Mature T-cell lymphoma, NOS	1	0	1
	9709	Cutaneous T-cell lymphoma, NOS	1	0	1
	9714	Anaplastic large cell lymphoma, T cell and Null cell type	2	1	3
	9727	Precursor cell lymphoblastic lymphoma, NOS	1	0	1
	9729	Precursor T-cell lymphoblastic lymphoma	0	2	2
c. Burkitt lymphoma	9687	Burkitt lymphoma, NOS	3	2	5
d. Miscellaneous lymphoreticular neoplasms	9751	Langherans cell histiocytosis, NOS	3	3	6
e. Unspecified lymphomas	9590	Malignant lymphoma, NOS	6	2	8
Total			50	35	85

Table 28 continued ...

ICCC-3 Site Group	ICD -O-3 Histology		Male	Female	Total	
CNS and miscellaneous						
III	intracranial and intraspinal neoplasms					
	a. Ependymomas and choroid plexus tumour	9391	Ependymoma, NOS	4	2	6
		9392	Ependymoma, anaplastic	3	0	3
	b. Astrocytoma	9400	Astrocytoma, NOS	2	2	4
		9424	Pleomorphic xanthoastrocytoma	1	1	2
		9440	Glioblastoma, NOS	1	1	2
	c. Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	11	4	15
		9471	Desmoplastic nodular medulloblastoma	1	1	2
	d. Other gliomas	9380	Glioma, malignant	7	9	16
		9451	Oligodendrogioma, anaplastic	1	0	1
	f. Unspecified intracranial and intraspinal neoplasms	8000	Neoplasm, malignant	4	5	9
	Total			35	25	60
Neuroblastoma and other peripheral nervous cell tumours						
IV	Neuroblastoma and other peripheral nervous cell tumours					
	a. Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	6	6	12
		9500	Neuroblastoma, NOS	11	11	22
	b. Other peripheral nervous cell tumour	8680	Paraganglioma, malignant	0	1	1
		8700	Pheochromocytoma, malignant	1	0	1
	Total			18	18	36
V	Retinoblastoma					
	Retinoblastoma	9510	Retinoblastoma, NOS	15	19	34
	Total			15	19	34

Table 28 continued ...

ICCC-3 Site Group	ICD -O-3 Histology		Male	Female	Total
VI Renal tumours					
a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	13	18	31
	8964	Clear cell sarcoma of kidney	2	0	2
B. Renal carcinomas	8312	Renal cell carcinoma, NOS	0	2	2
Total			15	20	35
VII Hepatic tumours					
a. Hepatoblastoma	8970	Hepatoblastoma	10	5	15
b. Hepatic carcinomas	8170	Hepatocellular carcinoma, NOS	2	1	3
c. Unspecified hepatic tumours	8000	Neoplasm, malignant	1	0	1
Total			13	6	19
VIII Malignant bone tumours					
a. Osteosarcomas	9180	Osteosarcoma, NOS	23	17	40
	9181	Chondroblastic osteosarcoma	2	1	3
	9183	Telangiectatic osteosarcoma	0	1	1
	9186	Central Osteosarcoma	3	1	4
b. Chondrosarcomas	9220	Chondrosarcoma, NOS	2	0	2
c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	12	14	26
e. Unspecified malignant bone tumours	8000	Neoplasm, malignant	3	0	3
	8800	Sarcoma, NOS	1	2	1
Total			46	34	80
IX Soft tissue and other extraosseous sarcoma					
a. Rhabdomyosarcoma	8900	Rhabdomyosarcoma, NOS	7	4	11
	8910	Embryonal rhabdomyosarcoma, NOS	0	3	3
	8912	Spindle cell rhabdomyosarcoma	1	0	1

Table 28 continued ...

ICCC-3 Site Group		ICD -O-3 Histology	Male	Female	Total	
	8920	Alveolar rhabdomyosarcoma	1	0	1	
b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms.	8813	Fascial fibrosarcoma	0	1	1	
	9540	Malignant peripheral nerve sheath tumour	0	1	1	
	9580	Granular cell tumour, malignant	1	0	1	
d. Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumour	19	12	31	
	8830	Malignant fibrous histiocytoma	0	1	1	
	8832	Dermatofibrosarcoma, NOS	1	0	1	
	8854	Pleomorphic liposarcoma	0	1	1	
	9040	Synovial sarcoma, NOS	3	1	4	
	9041	Synovial sarcoma, spindle cell	1	0	1	
	9043	Synovial sarcoma, biphasic	1	0	1	
	9130	Hemangioendothelioma, malignant	0	1	1	
	9260	Ewing sarcoma	3	0	3	
	9581	Alveolar soft part sarcoma	1	0	1	
e. Unspecified soft tissue sarcomas	8800	Sarcoma, NOS	8	3	11	
Total			47	28	75	
<hr/>						
X	Germ cell tumours, trophoblastic tumours, and neoplasms of gonads					
	a. Intracranial and intraspinal germ cell tumours	9064	Germinoma	2	1	3
		9070	Embryonal carcinoma, NOS	3	0	3
		9085	Mixed germ cell tumour	1	0	1
	b. Malignant extracranial and extragonadal germ cell tumours	9060	Dysgerminoma	0	1	1
		9064	Germinoma	1	0	1

Table 28 continued ...

ICCC-3 Site Group	ICD -O-3 Histology		Male	Female	Total
	9070	Embryonal carcinoma, NOS	1	0	1
	9071	Yolk sac tumour	1	2	3
	9080	Teratoma, malignant, NOS	0	1	1
	9085	Mixed germ cell tumour	2	3	5
c. Malignant gonadal germ cell tumours	9060	Dysgerminoma	0	9	9
	9064	Germinoma	2	5	7
	9065	Germ cell tumour, nonseminomatous	1	1	2
	9070	Embryonal carcinoma, NOS	0	2	2
	9071	Yolk sac tumour	2	10	12
	9080	Teratoma, malignant, NOS	1	2	3
	9085	Mixed germ cell tumour	1	6	7
d. Gonadal carcinomas	8441	Serous cystadenocarcinoma, NOS	0	3	3
	8450	Papillary cystadenocarcinoma, NOS	0	1	1
	8480	Mucinous adenocarcinoma	0	1	1
e. Other and unspecified malignant gonadal tumours	8000	Neoplasm, malignant	1	3	4
	8620	Granulosa cell tumour, malignant	0	2	2
	8631	Sertoli-Leydig cell tumour, poorly differentiated	0	1	1
Total			19	54	73
XI Other malignant epithelial neoplasms and malignant melanomas	b. Thyroid carcinomas				
	8050	Papillary carcinoma, NOS	0	4	4
	8260	Papillary adenocarcinoma, NOS	9	29	38
	8290	Oxyphilic adenocarcinoma	0	1	1
	8330	Follicular adenocarcinoma, NOS	1	10	11
	8335	Follicular carcinoma, minimally invasive	1	1	2
	8340	Papillary carcinoma, follicular variant	0	5	5

Table 28 continued ...

ICCC-3 Site Group	ICD -O-3 Histology	Male	Female	Total
	8341 Papillary microcarcinoma	0	3	3
	8346 Mixed medullary-follicular carcinoma	0	1	1
c. Nasopharyngeal carcinomas	8070 Squamous cell carcinoma, NOS	1	1	2
	8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
d. Malignant melanomas	8720 Malignant melanoma, NOS (<i>except juvenile melanoma M-8770/0</i>)	0	1	1
	8744 Acral lentiginous melanoma, malignant	0	1	1
e. Skin carcinomas	8031 Giant cell carcinoma	1	0	1
	8070 Squamous cell carcinoma, NOS	2	1	3
	8390 Skin appendage carcinoma	1	0	1
f. Other and unspecified carcinomas	8010 Carcinoma, NOS	0	1	1
	8070 Squamous cell carcinoma, NOS	1	4	5
	8120 Transitional cell carcinoma, NOS	2	0	2
	8130 Papillary transitional cell carcinoma	1	0	1
	8140 Adenocarcinoma, NOS	4	1	5
	8240 Carcinoid tumour, NOS	2	0	2
	8246 Neuroendocrine carcinoma, NOS	3	1	4
	8430 Mucoepidermoid carcinoma	4	6	10
	8452 Solid pseudopapillary carcinoma	0	1	1
	8480 Mucinous adenocarcinoma	1	1	2
	8502 Secretory carcinoma of breast	0	1	1
	8503 Intraductal papillary adenocarcinoma with invasion	0	1	1
Total		35	75	110

Table 28 continued ...

ICCC-3 Site Group	ICD -O-3 Histology		Male	Female	Total
XII Other and unspecified malignant neoplasms					
a. Other specified malignant tumours	8935	Stromal sarcoma, NOS	0	1	1
	8936	Gastrointestinal stromal sarcoma	1	0	1
b. Other unspecified malignant tumours	8000	Neoplasm, malignant	19	13	32
	8004	Malignant tumour, spindle cell type	3	2	5
Total			23	16	39
All sites			449	413	862

Table 29: Overall cancer incidence by province and district in Sri Lanka, 2017

Province	District	Male		Female		Total	
		No	%	No	%	No	%
Western	Not known	8571	55.4	9937	59.5	18508	57.5
		3618	23.4	4132	24.7	7750	24.1
	Colombo	2202	14.2	2437	14.6	4639	14.4
	Gampaha	894	5.8	1035	6.2	1929	6
Central	Kalutara	522	3.4	660	3.9	1182	3.7
		1053	6.8	1370	8.2	2423	7.5
	Kandy	598	3.9	744	4.5	1342	4.2
	Matale	225	1.5	285	1.7	510	1.6
Southern	NuwaraEliya	230	1.5	341	2	571	1.8
		882	5.7	1006	6	1888	5.9
	Galle	440	2.8	485	2.9	925	2.9
	Hambanthota	153	1	176	1.1	329	1
Northern	Matara	289	1.9	345	2.1	634	2
		455	2.9	527	3.2	982	3.1
	Jaffna	329	2.1	336	2	665	2.1
	Kilinochchi	35	0.2	47	0.3	82	0.3
Eastern	Mannar	27	0.2	36	0.2	63	0.2
	Mullaitivu	33	0.2	41	0.2	74	0.2
	Vavuniya	31	0.2	67	0.4	98	0.3
		201	1.3	273	1.6	474	1.5
North Western	Ampara	100	0.6	117	0.7	217	0.7
	Batticaloa	54	0.3	88	0.5	142	0.4
	Trincomalee	47	0.3	68	0.4	115	0.4
		1161	7.5	1162	7	2323	7.2
North Central	Kurunegala	916	5.9	897	5.4	1813	5.6
	Puttalam	245	1.6	265	1.6	510	1.6
		270	1.7	293	1.8	563	1.8
	Anuradhapura	147	1	156	0.9	303	0.9
Uva	Polonnaruwa	123	0.8	137	0.8	260	0.8
		308	2	510	3.1	818	2.5
	Badulla	227	1.5	361	2.2	588	1.8
	Moneragala	81	0.5	149	0.9	230	0.7
Sabaragamuwa		623	4	664	4	1287	4
	Ratnapura	272	1.8	303	1.8	575	1.8
	Kegalle	351	2.3	361	2.2	712	2.2
	Total	15458	100	16712	100	32170	100

Table 30: Leading cancer incidence data by district in Sri Lanka, 2017**Western Province****Colombo**

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	671	27.7	14.5
2	C18-C20 Colon and Rectum	393	16.2	8.5
3	C33-C34 Trachea, bronchus and lung	326	13.5	7.0
4	C00-C06 Lip, Tongue and Mouth	286	11.8	6.2
5	C61 Prostate	211	8.7	4.5
6	C56 Ovary	196	8.1	4.2
7	C73 Thyroid	184	7.6	4.0
8	C54-C55 Uterus	177	7.3	3.8
9	C15 Oesophagus	164	6.8	3.5
10	C22 Liver	158	6.5	3.4
All sites		4639	191.8	100.0

Gampaha

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	349	14.6	18.1
2	C00-C06 Lip, Tongue and Mouth	183	7.7	9.5
3	C33-C34 Trachea, bronchus and lung	154	6.4	8.0
4	C73 Thyroid	148	6.2	7.7
5	C18-C20 Colon and Rectum	140	5.9	7.3
6	C56 Ovary	100	4.2	5.2
7	C81-C85, C96 Lymphoma	86	3.6	4.5
8	C91-95 Leukaemia	76	3.2	3.9
9	C09-C14 Pharynx	72	3.0	3.7
10	C15 Oesophagus	71	3.0	3.7
All sites		1929	80.7	100.0

Kalutara

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	215	16.9	18.2
2	C00-C06 Lip, Tongue and Mouth	129	10.1	10.9
3	C18-C20 Colon and Rectum	92	7.2	7.8
4	C73 Thyroid	89	7.0	7.5
5	C33-C34 Trachea, bronchus and lung	55	4.3	4.7
6	C56 Ovary	53	4.2	4.5
7	C15 Oesophagus	51	4.0	4.3
8	C53 Cervix	45	3.5	3.8
9	C81-C85, C96 Lymphoma	45	3.5	3.8
10	C91-95 Leukaemia	44	3.5	3.7
All sites		1182	93.0	100.0

Central Province**Kandy**

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	215	14.8	16.0
2	C18-C20 Colon and Rectum	131	9.0	9.8
3	C15 Oesophagus	107	7.4	8.0
4	C00-C06 Lip, Tongue and Mouth	92	6.3	6.9
5	C33-C34 Trachea, bronchus and lung	87	6.0	6.5
6	C73 Thyroid	85	5.9	6.3
7	C81-C85, C96 Lymphoma	59	4.1	4.4
8	C54-C55 Uterus	53	3.7	3.9
9	C56 Ovary	50	3.4	3.7
10	C91-95 Leukaemia	50	3.4	3.7
All sites		1342	92.4	100.0

Matale

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	79	15.4	15.5
2	C15 Oesophagus	46	8.9	9.0
3	C73 Thyroid	43	8.4	8.4
4	C18-C20 Colon and Rectum	38	7.4	7.5
5	C00-C06 Lip, Tongue and Mouth	31	6.0	6.1
6	C81-C85, C96 Lymphoma	31	6.0	6.1
7	C09-C14 Pharynx	23	4.5	4.5
8	C54-C55 Uterus	22	4.3	4.3
9	C56 Ovary	21	4.1	4.1
10	C32 Larynx	20	3.9	3.9
All sites		510	99.2	100.0

Nuwara Eliya

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	66	8.7	11.6
2	C00-C06 Lip, Tongue and Mouth	62	8.2	10.9
3	C15 Oesophagus	55	7.3	9.6
4	C73 Thyroid	46	6.1	8.1
5	C18-C20 Colon and Rectum	35	4.6	6.1
6	C16 Stomach	31	4.1	5.4
7	C53 Cervix	31	4.1	5.4
8	C33-C34 Trachea, bronchus and lung	27	3.6	4.7
9	C91-95 Leukaemia	23	3.0	4.0
10	C09-C14 Pharynx	20	2.6	3.5
11	C81-C85, C96 Lymphoma	20	2.6	3.5
All sites		571	75.5	100.0

Southern Province**Galle**

Rank	ICD code and site	Cases	CR	%
1	C73 Thyroid	104	9.3	11.2
2	C50 Breast	96	8.6	10.4
3	C18-C20 Colon and Rectum	87	7.8	9.4
4	C33-C34 Trachea, bronchus and lung	61	5.5	6.6
5	C15 Oesophagus	60	5.4	6.5
6	C81-C85, C96 Lymphoma	51	4.6	5.5
7	C56 Ovary	44	4.0	4.8
8	C53 Cervix	43	3.9	4.6
9	C00-C06 Lip, Tongue and Mouth	41	3.7	4.4
10	C09-C14 Pharynx	39	3.5	4.2
All sites		925	83.1	100.0

Hambanthota

Rank	ICD code and site	Cases	CR	%
1	C73 Thyroid	41	6.3	12.5
2	C00-C06 Lip, Tongue and Mouth	38	5.9	11.6
3	C33-C34 Trachea, bronchus and lung	24	3.7	7.3
4	C18-C20 Colon and Rectum	23	3.6	7.0
5	C50 Breast	23	3.6	7.0
6	C81-C85, C96 Lymphoma	21	3.2	6.4
7	C56 Ovary	19	2.9	5.8
8	C15 Oesophagus	14	2.2	4.3
9	C61 Prostate	13	2.0	4.0
10	C22 Liver	12	1.9	3.6
All sites		329	50.9	100.0

Matara

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	82	9.6	12.9
2	C73 Thyroid	68	8.0	10.7
3	C00-C06 Lip, Tongue and Mouth	56	6.6	8.8
4	C18-C20 Colon and Rectum	56	6.6	8.8
5	C33-C34 Trachea, bronchus and lung	37	4.3	5.8
6	C81-C85, C96 Lymphoma	34	4.0	5.4
7	C15 Oesophagus	31	3.6	4.9
8	C91-95 Leukaemia	25	2.9	3.9
9	C53 Cervix	23	2.7	3.6
10	C56 Ovary	23	2.7	3.6
All sites		634	74.5	100.0

Northern Province**Jaffna**

Rank	ICD code and site	Cases	CR	%
1	C00-C06 Lip, Tongue and Mouth	107	37.5	16.1
2	C50 Breast	86	30.1	12.9
3	C73 Thyroid	57	20.0	8.6
4	C15 Oesophagus	53	18.6	8.0
5	C09-C14 Pharynx	41	14.4	6.2
6	C18-C20 Colon and Rectum	31	10.9	4.7
7	C53 Cervix	27	9.5	4.1
8	C56 Ovary	27	9.5	4.1
9	C61 Prostate	24	8.4	3.6
10	C54-C55 Uterus	18	6.3	2.7
All sites		665	233.0	100.0

Kilinochchi

Rank	ICD code and site	Cases	CR	%
1	C73 Thyroid	12	9.7	14.6
2	C50 Breast	10	8.0	12.2
3	C00-C06 Lip, Tongue and Mouth	9	7.2	11.0
4	C09-C14 Pharynx	6	4.8	7.3
5	C53 Cervix	6	4.8	7.3
6	C56 Ovary	6	4.8	7.3
7	C15 Oesophagus	4	3.2	4.9
8	C16 Stomach	3	2.4	3.7
9	C40-C41 Bone	3	2.4	3.7
10	C18-C20 Colon and Rectum	2	1.6	2.4
All sites		82	66.0	100.0

Mannar

Rank	ICD code and site	Cases	CR	%
1	C73 Thyroid	11	10.2	17.5
2	C50 Breast	9	8.4	14.3
3	C15 Oesophagus	5	4.7	7.9
4	C00-C06 Lip, Tongue and Mouth	4	3.7	6.3
5	C09-C14 Pharynx	4	3.7	6.3
6	C16 Stomach	4	3.7	6.3
7	C18-C20 Colon and Rectum	4	3.7	6.3
8	C64 Kidney	4	3.7	6.3
9	C23-C24 Gall bladder and biliary tract	2	1.9	3.2
10	C56 Ovary	2	1.9	3.2
11	C81-C85, C96 Lymphoma	2	1.9	3.2
12	C91-95 Leukaemia	2	1.9	3.2
All sites		63	58.6	100.0

Mullaithivu

Rank	ICD code and site	Cases	CR	%
1	C53	15	15.7	20.3
2	C00-C06	13	13.6	17.6
3	C50	6	6.3	8.1
4	C15	5	5.2	6.8
5	C73	4	4.2	5.4
6	C91-95	4	4.2	5.4
7	C81-C85, C96	3	3.1	4.1
8	C18-C20	2	2.1	2.7
9	C25	2	2.1	2.7
10	C61	2	2.1	2.7
11	C90	2	2.1	2.7
All sites		74	77.3	100.0

Vavuniya

Rank	ICD code and site	Cases	CR	%
1	C50	16	8.7	16.3
2	C53	15	8.1	15.3
3	C73	13	7.0	13.3
4	C00-C06	8	4.3	8.2
5	C15	7	3.8	7.1
6	C09-C14	5	2.7	5.1
7	C23-C24	4	2.2	4.1
8	C54-C55	3	1.6	3.1
9	C56	3	1.6	3.1
10	C91-95	3	1.6	3.1
All sites		98	53.1	100.0

Eastern Province**Ampara**

Rank	ICD code and site	Cases	CR	%
1	C50	Breast	30	4.3
2	C73	Thyroid	23	3.3
3	C91-95	Leukaemia	15	2.1
4	C00-C06	Lip, Tongue and Mouth	14	2.0
5	C56	Ovary	14	2.0
6	C18-C20	Colon and Rectum	12	1.7
7	C33-C34	Trachea, bronchus and lung	12	1.7
8	C70-C72	Brain and nervous system	12	1.7
9	C81-C85, C96	Lymphoma	12	1.7
10	C15	Oesophagus	9	1.3
11	C32	Larynx	9	1.3
12	C53	Cervix	9	1.3
All sites		217	30.8	100.0

Batticaloa

Rank	ICD code and site	Cases	CR	%
1	C50	Breast	33	5.9
2	C53	Cervix	17	3.0
3	C33-C34	Trachea, bronchus and lung	14	2.5
4	C73	Thyroid	10	1.8
5	C91-95	Leukaemia	10	1.8
6	C18-C20	Colon and Rectum	8	1.4
7	C15	Oesophagus	6	1.1
8	C00-C06	Lip, Tongue and Mouth	5	0.9
9	C09-C14	Pharynx	5	0.9
10	C54-C55	Uterus	5	0.9
11	C56	Ovary	5	0.9
12	C81-C85, C96	Lymphoma	5	0.9
All sites		142	25.4	100.0

Trincomalee

Rank	ICD code and site	Cases	CR	%
1	C73	Thyroid	16	3.9
2	C00-C06	Lip, Tongue and Mouth	10	2.4
3	C50	Breast	9	2.2
4	C91-95	Leukaemia	9	2.2
5	C81-C85, C96	Lymphoma	8	1.9
6	C53	Cervix	7	1.7
7	C56	Ovary	7	1.7
8	C70-C72	Brain and nervous system	7	1.7
9	C33-C34	Trachea, bronchus and lung	6	1.5
10	C09-C14	Pharynx	4	1.0
11	C47, C49	Connective tissue and soft tissue	4	1.0
All sites		115	27.9	100.0

North Western Province**Kurunegala**

Rank	ICD code and site	Cases	CR	%
1	C00-C06	239	14.1	13.2
2	C50	234	13.8	12.9
3	C73	138	8.1	7.6
4	C15	133	7.9	7.3
5	C18-C20	119	7.0	6.6
6	C09-C14	84	5.0	4.6
7	C91-95	81	4.8	4.5
8	C56	79	4.7	4.4
9	C81-C85, C96	74	4.4	4.1
10	C33-C34	71	4.2	3.9
All sites		1813	107.0	100.0

Puttalam

Rank	ICD code and site	Cases	CR	%
1	C00-C06	81	10.0	15.9
2	C50	75	9.2	14.7
3	C73	39	4.8	7.6
4	C53	33	4.1	6.5
5	C18-C20	28	3.4	5.5
6	C33-C34	26	3.2	5.1
7	C54-C55	22	2.7	4.3
8	C56	22	2.7	4.3
9	C81-C85, C96	22	2.7	4.3
10	C15	20	2.5	3.9
All sites		510	62.7	100.0

North Central Province**Anuradhapura**

Rank	ICD code and site	Cases	CR	%
1	C73	Thyroid	43	4.7
2	C00-C06	Lip, Tongue and Mouth	36	3.9
3	C53	Cervix	36	3.9
4	C91-95	Leukaemia	24	2.6
5	C15	Oesophagus	16	1.7
6	C50	Breast	16	1.7
7	C18-C20	Colon and Rectum	14	1.5
8	C33-C34	Trachea, bronchus and lung	14	1.5
9	C09-C14	Pharynx	12	1.3
10	C32	Larynx	12	1.3
11	C70-C72	Brain and nervous system	12	1.3
12	C81-C85, C96	Lymphoma	12	1.3
All sites		303	33.0	100.0

Polonnaruwa

Rank	ICD code and site	Cases	CR	%
1	C73	Thyroid	42	9.7
2	C00-C06	Lip, Tongue and Mouth	39	9.1
3	C50	Breast	21	4.9
4	C18-C20	Colon and Rectum	19	4.4
5	C33-C34	Trachea, bronchus and lung	17	3.9
6	C91-95	Leukaemia	17	3.9
7	C09-C14	Pharynx	11	2.6
8	C32	Larynx	11	2.6
9	C56	Ovary	11	2.6
10	C15	Oesophagus	8	1.9
11	C70-C72	Brain and nervous system	8	1.9
All sites		260	60.3	100.0

Uva Province**Badulla**

Rank	ICD code and site	Cases	CR	%
1	C50 Breast	79	9.1	13.4
2	C73 Thyroid	60	6.9	10.2
3	C15 Oesophagus	46	5.3	7.8
4	C33-C34 Trachea, bronchus and lung	45	5.2	7.7
5	C53 Cervix	45	5.2	7.7
6	C18-C20 Colon and Rectum	43	5.0	7.3
7	C56 Ovary	34	3.9	5.8
8	C91-95 Leukaemia	24	2.8	4.1
9	C54-C55 Uterus	23	2.7	3.9
10	C81-C85, C96 Lymphoma	23	2.7	3.9
All sites		588	68.1	100.0

Moneragala

Rank	ICD code and site	Cases	CR	%
1	C73 Thyroid	71	14.6	30.9
2	C50 Breast	23	4.7	10.0
3	C15 Oesophagus	15	3.1	6.5
4	C53 Cervix	14	2.9	6.1
5	C00-C06 Lip, Tongue and Mouth	12	2.5	5.2
6	C18-C20 Colon and Rectum	11	2.3	4.8
7	C33-C34 Trachea, bronchus and lung	11	2.3	4.8
8	C54-C55 Uterus	9	1.9	3.9
9	C91-95 Leukaemia	9	1.9	3.9
10	C56 Ovary	7	1.4	3.0
All sites		230	47.5	100.0


Sabaragamuwa Province**Kegalle**



Rank	ICD code and site	Cases	CR	%
1	C50	100	11.4	14.0
2	C00-C06	78	8.9	11.0
3	C15	64	7.3	9.0
4	C56	42	4.8	5.9
5	C18-C20	41	4.7	5.8
6	C33-C34	37	4.2	5.2
7	C09-C14	36	4.1	5.1
8	C73	36	4.1	5.1
9	C81-C85, C96	33	3.8	4.6
10	C32	25	2.9	3.5
All sites		712	81.2	100.0



Ratnapura



Rank	ICD code and site	Cases	CR	%
1	C73	90	7.8	15.7
2	C00-C06	81	7.0	14.1
3	C50	65	5.6	11.3
4	C18-C20	38	3.3	6.6
5	C15	33	2.9	5.7
6	C53	28	2.4	4.9
7	C33-C34	21	1.8	3.7
8	C91-95	20	1.7	3.5
9	C81-C85, C96	19	1.7	3.3
10	C09-C14	18	1.6	3.1
All sites		575	49.9	100.0

Figure 59: Cancer incidence data by districts among males in Sri Lanka, 2017






















Figure 60: Cancer incidence data by districts among females in Sri Lanka, 2017











Cancer Mortality Data of Sri Lanka

Mortality data due to cancers were obtained through Annual Health Bulletin of Ministry of Health based on Indoor Morbidity Mortality Return (IMMR).

Cause of death data reported to vital registration system of Sri Lanka for year 2017 is not published by the Registrar General Department or Department of Census and Statistics yet. Therefore, total number of cancer deaths or number of cancer deaths according to ICD-10 site is not available currently.

Table 31: Deaths due to cancers among males & females in hospitals in Sri Lanka, 2012-2017

Year	No. of hospital deaths due to cancers		
	Male	Female	Total
2005	-	-	2753
2006	-	-	3241
2007	-	-	3498
2008	-	-	3485
2009	-	-	3774
2010	-	-	4449
2011	-	-	4631
2012	2538	1931	4519
2013	2559	1980	4539
2014	2867	2128	4995
2015	2657	2141	4798
2016	2878	2270	5148
2017	2720	2218	4938

Sources: Annual Health Bulletin 2005 to 2017

Table 32: Deaths due to cancers in hospitals, crude hospital annual death rates due to cancers and proportionate mortality ratio for cancers out of all hospital deaths in Sri Lanka, 2005-2017

Year	No. of hospital deaths due to cancers	Crude hospital annual death rate due to cancers per 100,000 population	Proportionate Mortality Ratio (PMR) out of all hospital deaths
2005	2753	14.0	8.3
2006	3241	16.3	9.9
2007	3498	17.5	10.1
2008	3485	17.2	9.8
2009	3774	18.5	10.0
2010	4449	21.5	11.1
2011	4631	22.2	11.8
2012	4519	22.2	11.6
2013	4539	22.2	11.2

Year	No. of hospital deaths due to cancers	Crude hospital annual death rate due to cancers per 100,000 population	Proportionate Mortality Ratio (PMR) out of all hospital deaths
2014	4995	24.0	11.7
2015	4798	22.9	11.0
2016	5148	24.3	12.0
2017	4938	23.0	10.5

Sources: Annual Health Bulletin 2005 to 2017

Table 33: Hospitalizations, hospital deaths and case fatality rate due to cancers in year 2017 by RDHS divisions in Sri Lanka

*RDHS Area	Hospital Admissions due to cancers			**Case fatality rate
	Total hospital admissions	Live hospital discharges	No. hospital deaths	
Colombo	62113	60123	1990	3.2
Gampaha	4393	4186	207	4.71
Kalutara	1873	1805	68	3.63
Kandy	13723	13137	586	4.27
Matale	797	752	45	5.65
Nuwara Eliya	943	893	50	5.3
Galle	14625	14216	409	2.8
Matara	809	763	46	5.69
Hambanthota	674	614	60	8.9
Jaffna	5369	5224	145	2.7
Kilinochchi	289	282	7	2.42
Mullaitivu	59	54	5	8.47
Vavuniya	332	311	21	6.33
Mannar	231	225	6	2.6
Batticaloa	1457	1447	10	0.69
Ampara	271	242	29	10.7
Kalmunai	234	220	14	5.98
Trincomalee	1456	1436	20	1.37
Kurunegala	4820	4438	382	7.93
Puttalam	642	609	33	5.14
Anuradhapura	5301	5063	238	4.49
Polonnaruwa	861	784	77	8.94
Badulla	6084	5895	189	3.11
Moneragala	847	809	38	4.49
Ratnapura	5808	5613	195	3.36
Kegalle	998	930	68	6.81
Sri Lanka	135009	130071	4938	3.66

RDHS divisions – Regional Director of health Services divisions

$$\text{**Case Fatality rate} = \frac{\text{No. of hospital deaths due to cancers}}{\text{Total number of hospital admissions due to cancers}} \times 100$$

Annex

Table 1 Summary details of previous publications of 'Cancer Incidence Data Sri Lanka'

Year of cancer incidence data	Data generating centres						Publication	
	Cancer Treatment Centres	Pathology laboratories	OMF units	Medical Record Rooms	Death Registrars	Total no. of centres	Volume	Year published
1985	3	—	—	—	—	3	1	1990
1986	3	—	—	—	—	3	2	1991
1987	3	—	—	—	—	3	3	1993
1990	3	—	—	—	—	3	4	1996
1995	3	—	—	—	—	3	5	2002
2000	4	—	—	—	—	4	6	2006
2001-2005	5	—	—	—	—	5	7	2009
2006	6	—	4	—	—	10	8	2012
2007	6	—	4	—	—	10	9	2013
2008	7	16	17	—	—	40	10	2014
2009	9	15	17	—	—	41	11	2015
2010	9	13	17	—	—	39	12	2016
2011	9	13	12	—	—	34	13	2018
2012	9	37	15	9	—	70	14	2020
2013	9	45	15	25	—	94	15	2020
2014	9	51	15	24	40	139	16	2020
2015	9	58	15	24	40	146	17	2021
2016	14	53	22	22	40	151	18	2021

Statistical Terminology

Population at risk

The population at risk includes all individuals susceptible to a specific cancer. It is defined on the basis of demographic variables, such as place of residence, sex, age group. Years of risk duration are counted in person-years.

Incidence

Incidence quantifies the number of new cases that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

Mortality

Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.

$$\text{Crude incidence rate} = \frac{\text{Total number of cases in the year}}{\text{Total midyear population at risk}} \times 100,000$$

$$\text{Crude death rate} = \frac{\text{Total number of deaths in the year}}{\text{Total midyear population at risk}} \times 100,000$$

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five-year age categories are used.

$$\text{Age-specific incidence rate} = \frac{\text{Number of cases in the five-year age group} \times 100,000}{\text{Population at risk in the corresponding age group}}$$

$$\text{Age-specific death rate} = \frac{\text{Number of deaths in the five-year age group} \times 100,000}{\text{Population at risk in the corresponding age group}}$$

ASR (Age standardized rate)

An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of dying from cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the *standard population*. The most frequently used standard population is the *World Standard Population*. The calculated mortality rate is then called age-standardised mortality rate (world). The world standard population used within the application is as proposed by Segi (1960) and modified by Doll and *al.* (1966). The ASR is also expressed per 100,000.

Age distribution of the world standard population	
Age group	w _i
0-4	12000
5-9	10000
10-14	9000
15-19	9000
20-24	8000
25-29	8000
30-34	6000
35-39	6000
40-44	6000
45-49	6000
50-54	5000
55-59	4000
60-64	4000
65-69	3000
70-74	2000
75-79	1000
80-84	500
85+	500
Total	100000

Life time risk (Cumulative Risk)

Cumulative incidence/mortality is the probability or risk of individuals getting/dying from the disease within a specified age interval within a time period.

(The cumulative risk is the risk which an individual would have of developing the cancer under study during a certain age span if no other causes of death were in operation)

List of References

1. Department of Census and Statistics. (2021). Retrieved 20 August 2021, from <http://www.statistics.gov.lk/Population/Staticallnformation/VitalStatistics>
2. World Health Organization. (2013). International classification of diseases for oncology (ICD-O) – 3(1). World Health Organization. <https://apps.who.int/iris/handle/10665/96612>
3. International Association of Research on Cancer. (2010). *Glossary of terms*. Retrieved 15 August 2021, from <https://www-dep.iarc.fr/WHOdb/glossary.htm>.
4. World Health Organization. (2016). International statistical classification of diseases and related health problems: ICD 10 – 5(1). World Health Organization. Retrieved from: <https://icd.who.int/browse10/Content/statichtml/ICD10Volume2en2016.pdf>
5. International Association of Research on Cancer. (2021). International Association of Cancer Registries. Retrieved 25 September 2021, from <http://www.iacr.com.fr/index.php>
6. Steliarova-Foucher, E., Stiller, C., Lacour, B., & Kaatsch, P. (2005). International classification of childhood cancer. *Cancer*, 103(7), 1457-1467.
7. Ministry of Health, Nutrition and Indigenous Medicine Sri Lanka. (2017). Annual Health Bulletin 2017. Retrieved 21 September 2021, from <http://www.health.gov.lk/mohfinal/english/public/elfinder/files/publications/AHB/2017/AHB2016.pdf>



National Cancer Control Programme
Ministry of Health
555/5, Public Health Complex
Elvitigala Mawatha, Narahenpita,
Colombo 05, Sri Lanka
+94 11236 8627
www.nccp.health.gov.lk

9 786245 719150